Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

> A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Sunday, June 5, 2022 7:00 PM – 9:30 PM CT (8:00 PM – 10:30 PM ET)

Faculty

Ian W Flinn, MD, PhD Brian T Hill, MD, PhD John P Leonard, MD

Matthew Lunning, DO Laurie H Sehn, MD, MPH Mitchell R Smith, MD, PhD

Moderator Neil Love, MD



Faculty



Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee



Brian T Hill, MD, PhD Director, Lymphoid Malignancy Program Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio



John P Leonard, MD

Richard T Silver Distinguished Professor of Hematology and Medical Oncology Senior Associate Dean for Innovation and Initiatives Executive Vice Chair, Joan and Sanford I Weill Department of Medicine Weill Cornell Medicine New York, New York



Matthew Lunning, DO Associate Professor Fred and Pamela Buffett Cancer Center Associate Vice Chair of Research, Department of Medicine Assistant Vice Chancellor of Clinical Research University of Nebraska Medical Center Omaha, Nebraska



Laurie H Sehn, MD, MPH

Chair, Lymphoma Tumour Group BC Cancer Centre for Lymphoid Cancer Clinical Professor of Medicine Division of Medical Oncology University of British Columbia Associate Editor, *Blood* Vancouver, British Columbia, Canada



Mitchell R Smith, MD, PhD Clinical Professor of Medicine George Washington University Washington, DC



Moderator Neil Love, MD Research To Practice Miami, Florida



Clinicians in the Meeting Room

Networked iPads are available.



Review Program Slides: Tap the Program Slides button to review speaker presentations and other program content.



Answer Survey Questions: Complete the premeeting survey before the meeting. Survey results will be presented and discussed throughout the meeting.



Ask a Question: Tap Ask a Question to submit a challenging case or question for discussion. We will aim to address as many questions as possible during the program.



Complete Your Evaluation: Tap the CME Evaluation button to complete your evaluation electronically to receive credit for your participation.

For assistance, please raise your hand. Devices will be collected at the conclusion of the activity.



Clinicians Attending via Zoom

|--|

Review Program Slides: A link to the program slides will be posted in the chat room at the start of the program.



Answer Survey Questions: Complete the premeeting survey before the meeting. Survey results will be presented and discussed throughout the meeting.



Ask a Question: Submit a challenging case or question for discussion using the Zoom chat room.




Get CME Credit: A CME credit link will be provided in the chat room at the conclusion of the program.



About the Enduring Program

- The live meeting is being video and audio recorded.
- The proceedings from today will be edited and developed into an enduring web-based video/PowerPoint program.



An email will be sent to all attendees when the activity is available.

 To learn more about our education programs, visit our website, <u>www.ResearchToPractice.com</u>



Friday	Acute Myeloid Leukemia and Myelodysplastic Syndromes 11:45 AM – 12:45 PM CT (12:45 PM – 1:45 PM ET)
June 3	Lung Cancer 6:30 PM - 9:00 PM CT (7:30 PM - 10:00 PM ET)
Saturday	Prostate Cancer 6:45 AM - 7:45 AM CT (7:45 AM - 8:45 AM ET)
June 4	Gastrointestinal Cancers 7:00 PM - 9:30 PM CT (8:00 PM - 10:30 PM ET)
Sunday	Ovarian Cancer 6:45 AM – 7:45 AM CT (7:45 AM – 8:45 AM ET)
June 5	Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma 7:00 PM - 9:30 PM CT (8:00 PM - 10:30 PM ET)
Monday	Urothelial Bladder Cancer 6:45 AM - 7:45 AM CT (7:45 AM - 8:45 AM ET)
June 6	Breast Cancer 7:00 PM - 9:30 PM CT (8:00 PM - 10:30 PM ET)
Tuesday June 7	Multiple Myeloma 6:45 AM – 7:45 AM CT (7:45 AM – 8:45 AM ET)



Exciting CME Events in Chicago You Do Not Want to Miss

A CME Hybrid Symposium Series Held in Conjunction with the 2022 ASCO Annual Meeting

Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Sunday, June 5, 2022

7:00 PM – 9:30 PM CT (8:00 PM – 10:30 PM ET)

Faculty

Ian W Flinn, MD, PhD Brian T Hill, MD, PhD John P Leonard, MD Matthew Lunning, DO Laurie H Sehn, MD, MPH Mitchell R Smith, MD, PhD

Urothelial Bladder Cancer

Monday, June 6, 2022 6:45 AM – 7:45 AM CT (7:45 AM – 8:45 AM ET)

Faculty

Yohann Loriot, MD, PhD Elizabeth R Plimack, MD, MS Jonathan E Rosenberg, MD

Breast Cancer

Monday, June 6, 2022 7:00 PM – 9:30 PM CT (8:00 PM – 10:30 PM ET)

Faculty

Javier Cortés, MD, PhD Matthew P Goetz, MD Erika Hamilton, MD Ian E Krop, MD, PhD Hope S Rugo, MD Sara M Tolaney, MD, MPH

Multiple Myeloma

Tuesday, June 7, 2022 6:45 AM – 7:45 AM CT (7:45 AM – 8:45 AM ET)

Faculty Ajai Chari, MD Elizabeth O'Donnell, MD Robert Z Orlowski, MD, PhD



Spencer H Bachow, MD Lynn Cancer Institute Boca Raton, Florida



Shaachi Gupta, MD, MPH Florida Cancer Specialists Lake Worth, Florida



Philip L Brooks, MD Northern Light Eastern Maine Medical Center and Lafayette Family Cancer Institute Brewer, Maine



Shams Bufalino, MD Advocate Aurora Health Park Ridge, Illinois



Zanetta S Lamar, MD Florida Cancer Specialists Naples, Florida

Neil Morganstein, MD Atlantic Health System Summit, New Jersey



Lionel A Kankeu Fonkoua, MD Mayo Clinic Rochester, Minnesota



Vignesh Narayanan, MD Colorado Permanente Medical Group (CPMG) Lone Tree, Colorado





Namrata I Peswani, MD Harold C Simmons Comprehensive Cancer Center Richardson, Texas



Matthew R Strickland, MD Massachusetts General Hospital Cancer Center Boston, Massachusetts



Erik Rupard, MD The Reading Hospital West Reading, Pennsylvania



Commercial Support

This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Kite, A Gilead Company, and Lilly.

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.



Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.



Dr Flinn — Disclosures

Consulting Agreements (to Sarah Cannon Research Institute)	AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Great Point Partners LLC, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Unum Therapeutics, Verastem Inc, Vincerx Pharma, YL-Pharma Co Ltd
Research Grants (to Sarah Cannon Research Institute)	AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc



Dr Hill — Disclosures

Advisory Committee and Consulting Agreements	AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Epizyme Inc, Genentech, a member of the Roche Group, Kite, A Gilead Company, MorphoSys, Novartis			
Contracted Research	AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Kite, A Gilead Company, MorphoSys, Novartis			



Dr Leonard — Disclosures

Consulting Agreements	AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Grail Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Lilly, Merck, Mustang Bio, Pfizer Inc, Roche Laboratories Inc, Second Genome, Sutro Biopharma				
Contracted Research	Epizyme Inc, Genentech Foundation, Janssen Biotech Inc				
Data and Safety Monitoring Board/Committee	AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group				



Dr Lunning — Disclosures

Consulting Agreements	AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, EUSA Pharma, Fate Therapeutics, Genentech, a member of the Roche Group, Instil Bio, Kite, A Gilead Company, Kyowa Kirin Co Ltd, Legend Biotech, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Sana Biotechnology, TG Therapeutics Inc
-----------------------	--



Dr Sehn — Disclosures

Consulting Agreements	AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc			
Contracted Research	Genentech, a member of the Roche Group, Teva Oncology			



Dr Smith — Disclosures

Advisory Committee	Janssen Biotech Inc
Speakers Bureau	Acrotech Biopharma



Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

> A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Sunday, June 5, 2022 7:00 PM – 9:30 PM CT (8:00 PM – 10:30 PM ET)

Faculty

Ian W Flinn, MD, PhD Brian T Hill, MD, PhD John P Leonard, MD

Matthew Lunning, DO Laurie H Sehn, MD, MPH Mitchell R Smith, MD, PhD

Moderator Neil Love, MD



Agenda

Module 1 – Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Dr Flinn

Module 2 – Relapsed/Refractory (R/R) CLL; Novel Investigational Strategies — Dr Smith

Module 3 – Follicular Lymphoma (FL) — Dr Leonard

Module 4 – Mantle Cell Lymphoma (MCL) — Dr Lunning

Module 5 – Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn

Module 6 – Chimeric Antigen Receptor (CAR) T-Cell Therapy — Dr Hill



MODULE 1: Newly Diagnosed CLL – Dr Flinn



An 88-year-old woman with CLL, well controlled atrial fibrillation and a history of COPD and pneumonia



Dr Erik Rupard (West Reading, Pennsylvania)



A 73-year-old woman with CLL who developed severe basal cell carcinomas during ibrutinib therapy



Dr Zanetta Lamar (Naples, Florida)



An 80-year-old man with newly diagnosed del(13q) CLL and life-threatening anemia



Dr Namrata Peswani (Richardson, Texas)




Treatment Naïve CLL

Ian W. Flinn, MD, PhD Sarah Cannon Research Institute Tennessee Oncology

Current Approaches to Treatment of TN CLL: NCCN Guidelines[®]

	Without Del(1	.7p)/ <i>TP</i> 53	3 Mutation		
F	Patients age ≥65 years OR patients age <65 years with significant	Patients age <65 years without significant comorbidities			
Preferred	 comorbidities (CrCl <70 mL/min) Acalabrutinib ± obinutuzumab^a Ibrutinib^a Venetoclax + obinutuzumab^a 	Preferred	 Acalabrutinib ± obinutuzumab^a Ibrutinib^a Venetoclax + obinutuzumab Zanubrutinib 		
Other Regimens	 Zanubrutinib Bendamustine + anti-CD20 Chlorambucil + obinutuzumab Obinutuzumab High-dose methylprednisolone + rituximab or obinutuzumab Ibrutinib + obinutuzumab Chlorambucil 	Other Regimens	 Bendamustine + anti-CD20 Fludarabine + cyclophosphamide + rituximab^b Ibrutinib + rituximab Fludarabine + rituximab High-dose methylprednisolone + rituximab or obinutuzumab 		




NCCN Clinical Practice Guidelines® in Oncology for Chronic Lymphocytic Leukemia V.2.2022.

^a Category 1 preferred regimen. ^b Preferred for patients with *IGHV*-mutated CLL.


Up to 7 Years of Follow-Up in the RESONATE-2 Study of Ibrutinib for Patients With TN CLL: Treatment and Summary

PFS: Ibrutinib vs Chlorambucil



Most common reason for discontinuation over **7 years** was adverse event (23%); limited data available on next therapies


AEs of Clinical Interest Over Time With Ibrutinib



Ibrutinib Treatment Disposition	Ibrutinib n=136
Median (range) duration of ibrutinib treatment, years ^a	6.2 (0.06-7.2)
Continuing ibrutinib on study, n (%)	64 (47)
Discontinued ibrutinib, n (%)	
Adverse event	31 (23)
Progressive disease	16 (12)
Death	11 (8)
Withdrawal by patient	9 (7)
Investigator decision	4 (3)

ECOG 1912: IR vs FCR in Younger Patients With TN CLL

- Phase 3 trial of 529 patients with TN CLL aged ≤70 years who received either ibrutinib + rituximab (IR, n=354) or FCR (n=175)
- With a median follow-up of 48 months, 3-year PFS was 89% vs 71% in the IR and FCR arms, respectively (P<0.0001)
 - In IGHV-mut patients, difference in PFS between the IR and FCR arms was not statistically significant
- 3-year OS was 99% vs 93% in the IR and FCR arms, respectively (P=0.009)




Shanafelt TD, et al. ASH 2019. Abstract 33.

4-Year Follow-Up of ELEVATE-TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in TN CLL – Study Design and Patient Characteristics


 Key Eligibility Criteria Age ≥65 years or >18 to <65 years with comorbidities (defined as CrCl 30-69 mL/min and CIRS-G >6) 	Patient Chara	cteristics	A+0 (n=179)	A (n=179)	0+Clb (n=177)
 Untreated CLL requiring treatment per iwCLL 2008 criteria 	Median age (r	ange), years	70 (41-88)	70 (44-87)	71 (46-91)
 ECOG PS ≤2 No significant cardiovascular disease 	ECOG PS,	0-1	169 (94.4)	165 (92.2)	167 (94.4)
	n (%)	2	10 (5.6)	14 (7.8)	10 (5.6)
R <u>Acalabrutinib + Obinutuzumab (A+O)</u>	Bulky disease	Bulky disease ≥5 cm, n (%)		68 (38.0)	54 (30.5)
A Acala 100 mg po bid until PD or unacceptable toxicity Obinutuzumab 6 cycles	Rai stage, n (%)	III	47 (26.3)	51 (28.5)	40 (22.6)
		IV	38 (21.2)	37 (20.7)	38 (21.5)
O Acalabrutinib Monotherapy (A)	Cytogenetics, n (%)	del(17p)	17 (9.5)	16 (8.9)	16 (9.0)
Crossover from O+Clb to A allowed after IRC-confirmed PD		del(17p) and/or mut <i>TP</i> 53	25 (14.0)	23 (12.8)	25 (14.1)
Z E <u>Obinutuzumab + Chlorambucil (O+Clb)</u>		del(11q)	31 (17.3)	31 (17.3)	33 (18.6)
D 6 cycles		Complex karyotypeª	15 (8.4)	13 (7.3)	25 (14.1)
Primary endpoint: IRC-assessed PFS (A+O vs O+Clb)	Mutated TP53, n (%)		21 (11.7)	19 (10.6)	21 (11.9)
Secondary endpoints: IRC-assessed PFS (A vs O+Clb), INV-assessed PFS,	Unmutated IG	<i>HV</i> , n (%)	103 (57.5)	119 (66.5)	116 (65.5)
IRC- and INV- assessed INV- assessed ORR, TTNT, OS, uMRD, safety	Treatment ong	going, n (%)	134 (74.9)	124 (69.3)	0


Data cutoff: September 11, 2020 ^a Patients with \geq 3 chromosomal abnormalities. Sharman JP, et al. EHA 2021. Abstract S148.

4-Year Follow-Up of ELEVATE-TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in TN CLL – PFS and OS











INV-Assessed PFS In Unmutated IGHV



4-Year Follow-Up of ELEVATE-TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in TN CLL – Response




MRD Status in Patients With CR/CRi

INV-Assessed ORR

4-Year Follow-Up of ELEVATE-TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in TN CLL – Safety

AEa of Clinical Interact n (%)	A+O (n=178)		A (n=	179)	0+Clb (n=169)	
AEs of Clinical Interest, n (%)	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
Cardiac events	37 (20.8)	14 (7.9)	34 (19.0)	15 (8.4)	13 (7.7)	3 (1.8)
Atrial fibrillation	7 (3.9)	1 (0.6)	11 (6.1)	2 (1.1)	1 (0.6)	0
Bleeding	84 (47.2)	5 (2.8)	75 (41.9)	5 (2.8)	20 (11.8)	0
Major bleeding	7 (3.9)	5 (2.8)	7 (3.9)	5 (2.8)	2 (1.2)	0
Hypertension	14 (7.9)	6 (3.4)	13 (7.3)	5 (2.8)	7 (4.1)	6 (3.6)
Infections	134 (75.3)	42 (23.6)	132 (73.7)	29 (16.2)	75 (44.4)	14 (8.3)
Secondary primary malignancies	28 (15.7)	13 (7.3)	24 (13.4)	5 (2.8)	7 (4.1)	3 (1.8)
Excluding nonmelanoma skin	15 (8.4)	10 (5.6)	11 (6.1)	4 (2.2)	3 (1.8)	2 (1.2)

SEQUOIA: Phase 3 Open-Label Study of Zanubrutinib vs Bendamustine + Rituximab in TN CLL/SLL – Study Design and Efficacy




^a Bendamustine 90 mg/m² on day 1 and 2 and rituximab 375 mg/m² in cycle 1, 500 mg/m² in cycles 2-6 for 6 × 28-day cycles. 1. Tam CS, et al. ASH 2021. Abstract 396. 2. https://www.clinicaltrials.gov/ct2/show/NCT03336333.


ELEVATE-RR: Phase 3 Study of Acalabrutinib vs Ibrutinib in Patients With R/R CLL – Study Design and Results

Key Eligibility Criteria

- Previously treated CLL
- Presence of del(17p) and/or del(11q)
- ECOG PS ≤ 2
- No significant CV disease, no concomitant treatment with warfarin or equivalent VKA
- No prior treatment with ibrutinib, a BCRi, or a BCL-2i

Primary Endpoint: Noninferiority on IRC-Assessed PFS





Primary Endpoint Noninferiority on IRC-assessed PFS

Secondary Endpoints Incidence of any-grade atrial fibrillation/flutter, incidence of grade \geq 3 infection, incidence of RT, OS

Patient Characteristi	cs	Acala (n=268)	lbr (n=265)		
Median age, years (r	ange)	66 (41-89)	65 (28-88)		
ECOG PS 0-1, n (%)		247 (92)	243 (92)		
Bulky disease ≥5 cm	, n (%)	128 (48)	136 (51)		
Rai stage 3 or 4, n (%	6)	131 (49)	134 (51)		
Cytogenetics, n (%)	del(17p)	121 (45)	120 (45)		
	del(11q)	167 (62)	175 (66)		
	Complex karyotype ^a	124 (46)	125 (47)		
	TP53 mutated	100 (37)	112 (42)		
	IGHV unmutated	220 (82)	237 (89)		
Prior therapies, n (%)	Median (range)	2 (1-9)	2 (1-12)		
	1-3	234 (87)	237 (89)		
	≥4	33 (12)	28 (11)		

^a Patients with ≥3 chromosomal abnormalities. Hillmen P, et al. EHA 2021. Abstract S145. Seymour JF, et al. ASH 2021. Abstract 3721.

ELEVATE-RR: Phase 3 Study of Acalabrutinib vs Ibrutinib in Patients With R/R CLL – Post Hoc Safety Analysis


	Incidence, %			Exposure-Adjusted Incidence ^a			Exposure-Adjusted Time With Event ^b					
AEs	Any Grade		Grade ≥3		Any Grade		Grade ≥3		Any Grade		Grade ≥3	
	Acalac	lbr ^d	Acalac	lbr ^d	Acalac	lbr ^d	Acalac	lbr ^d	Acalac	lbr ^d	Acalac	lbr ^d
Events of clinical interest												
Cardiac events	24%	30%	9%	10%	1.2	1.9	0.4	0.5	7.1	13.0	0.4	0.2
Atrial fibrillation/flutter	9%	16%*	5%	4%	0.4	0.7	0.2	0.1	1.3	3.8	0.3	0.1
Hypertension ^e	9%	23%*	4%	9%*	0.4	1.2	0.1	0.4	4.1	15.0	1.6	4.0
Bleeding events ^f	38%	51%*	4%	5%	2.4	3.8	0.1	0.2	13.7	24.6	0.1	0.1
Major bleeding events ^g	5% ^h	5% ⁱ	4%	5%	0.2	0.2	0.1	0.2	0.1	0.3	0.1	0.1
Infections ^j	78%	81%	31%	30%	8.9	10.4	1.6	2.0	14.6	15.6	1.5	1.1
Selected common AEs ^k												
Diarrhea	35%	46%*	1%	5%*	1.9	2.8	<0.1	0.2	6.7	9.6	<0.1	0.1
Headache	35%*	20%	2%*	0	1.8	1.1	<0.1	0	7.8	5.4	<0.1	0
Cough	29%*	21%	1%	<1%	1.3	1.1	<0.1	<0.1	5.6	4.9	<0.1	<0.1
Fatigue	20%	17%	3%*	0	0.9	0.9	0.1	0	7.4	7.0	0.6	0
Arthralgia	16%	23%*	0	1%	0.6	1.3	0	<0.1	7.5	10.4	0	<0.1
Back pain	8%	13%*	0	1%	0.3	0.5	0	<0.1	1.9	3.2	0	0.1
Muscle spasms	6%	13%*	0	1%	0.2	0.7	0	<0.1	0.8	10.0	0	0.1
Dyspepsia	4%	12%*	0	0	0.1	0.5	0	0	1.0	2.4	0	0

- Median follow-up 40.9 months
- Treatment ongoing 46% (Acala) and 41% (lbr)
- Most common reasons for discontinuation PD (31% Acala vs 26% lbr), AEs (15% Acala vs 22% lbr)
- Median (range) treatment exposure 38.3 months (0.3-55.9) Acala vs 35.5 (0.2-57.7) lbr

≥5% incidence difference between arms are highlighted; green favors acalabrutinib, red favors ibrutinib. * Two-sided P value <0.05 without multiplicity adjustment, for comparison of incidence based on Barnard's exact test.


^a Reported as events per 100 person-months. ^b Reported as months with event per 100 person-months. ^c n=266. ^d n=263. ^e Includes hypertension, blood pressure increased, and blood pressure systolic increased. ^f Bleeding events occurring in \geq 10% of patients in either treatment arm include contusion and epistaxis. ^g Any hemorrhagic event that was serious, grade \geq 3, or a CNS hemorrhage (any grade). ^h Of 12 patients with major hemorrhage events in the Acala arm, CNS-related hemorrhage events were reported in 4 patients. Of 14 patients with major hemorrhage events in the Ibru arm, CNS-related hemorrhage events were reported in 1 patient who had 2 events. ¹Infections occurring in ≥10% of patients in either treatment arm include upper respiratory tract infection, pneumonia, bronchitis, nasopharyngitis, and urinary tract infection, ^kAEs occurring in ≥10% of patients in either treatment arm that are not already captured in the ECIs presented. Seymour JF, et al. ASH 2021. Abstract 3721.

ALPINE: Phase 3 Study of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL – Study Design and Results



^a 2 patients with missing values. ^b In safety analysis population. ^c Cardiac disorders leading to treatment discontinuation: 0 patients (zanubrutinib) vs 7 (3.4%) patients (ibrutinib). ^d Includes hemorrhages that were serious or grade ≥3 or CNS hemorrhages of all grades.
 ^e Pooled terms including neutropenia, neutrophil count decreased, and febrile neutropenia; thrombocytopenia and platelet count decreased. Hillmen P, et al. EHA 2021. Abstract LB1900.


ALPINE: PFS



 Guidelines include zanubrutinib as an option in patients with relapsed/refractory CLL/SLL or frontline CLL with TP53 mutation and an intolerance or contraindication to other BTKis

Hillmen. EHA 2021. Abstr 1900.


CLL14: 4-Year Follow-Up of Phase 3 Study of Venetoclax + Obinutuzumab vs Chlorambucil + Obinutuzumab – Study Design and Efficacy



CLL14: 4-Year Follow-Up of Phase 3 Study of Venetoclax + Obinutuzumab vs Chlorambucil + Obinutuzumab – PFS by Mutational Status

PFS by TP53 Status

PFS by IGHV Status



Time to Event [PFS] (months)

CLL14: 4-Year Follow-Up of Phase 3 Study of Venetoclax + Obinutuzumab vs Chlorambucil + Obinutuzumab – Safety

		n-G 212)		b-G 214)	Secondary Primary Malignancies (SPM)	Ven-G (n=212)	Clb-G (n=214)
Most Frequent					Overall total number of events, n	47	42
Grade ≥3 AEs,%	During	After	During	After	Number of pts with \geq 1 SPM, n (%)	40 (18.9)	30 (14.0)
	treatment	treatment	treatment	treatment	Non-melanoma skin cancer	19 (8.9)	18 (8.4)
				Melanoma	8 (3.7)	3 (1.4)	
Neutropenia	51.9	4.0	47.2	1.9	Prostate cancer	4 (1.8)	3 (1.4)
Thrombocytopenia	13.7	0.5	15.0	0.0	Colon cancer	2 (0.9)	2 (0.9)
Anemia	7.5	1.5	6.1	0.5	Lung cancer	2 (0.9)	2 (0.9)
Febrile neutropenia	4.2	1.0	3.3	0.5	Bladder cancer	2 (0.9)	0
					Breast cancer	2 (0.9)	0
Leukopenia	2.4	0.0	4.7	0.0	Hepatocellular carcinoma	0	1(0.5)
Pneumonia	3.3	3.0	2.8	1.4	Pancreatic cancer	0	1 (0.5)
Infusion-related reaction	9.0	0.0	9.8	0.5	Hematologic cancer	3 (1.4)	1
Tumor lysis syndrome	1.4	0.0	3.3	0.0	Other	2 (0.5)	3 (1.4)

GLOW: Phase 3 Study of Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in TN CLL – Study Design and Results




- Previously untreated CLL
- ≥65 years of age or <65 years with CIRS >6 or CrCl <70 mL/min
- No del(17p) or known TP53 mutation
- ECOG PS ≤ 2

Ibrutinib 420 mg po qd lead-in (3 cycles) followed by Ibrutinib + Venetoclax (I+V) (12 cycles; venetoclax ramp-up 20-400 mg over 5 weeks beginning C4) n=106 Chlorambucil (Clb) 0.5 mg/kg on D1 & D15 x 6 cycles +

on D1 & D15 x 6 cycles + <u>Obinutuzumab (O)</u> 1000 mg D1-2, D8, D15 of C1, and D1 of C2-6 n=105 Primary endpoint: IRC-assessed PFS Current MRD analysis

- MRD reported with cutoffs of $<10^{-4}$ and $<10^{-5}$
- PB/BM concordance calculated for patients with uMRD in PB at EOT+3 who had paired BM sample
- PFS results updated with 34.1 months of follow-up



R

A

N

D

0

Μ


Ζ

1:1

Safety (Median Follow-Up of 27.7 Months) ²	I+V (N=106)	Clb+0 (N=105)
Median exposure, mo (range)	13.8 (0.7-19.5)	5.1 (1.8-7.9)
Grade 3 or Higher AEs in \geq 5% of Patients, %	75.5	69.5
Neutropenia ^a	34.9	49.5
Infections ^b	17.0	11.4
Thrombocytopenia	5.7	20.0
Diarrhea	10.4	1.0
Hypertension	7.5	1.9
Atrial fibrillation	6.6	0
Hyponatremia	5.7	0
TLS	0	5.7

^a Includes neutrophil count decreased; grade ≥3 febrile neutropenia: 1.9% for I+V vs 2.9% for Clb+O. ^b Includes multiple preferred terms. 1. Munir T, et al. ASH 2021. Abstract 70. 2. Kater A, et al. EHA 2021.Abstract LB1902.

GLOW: Phase 3 Study of Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in TN CLL – MRD Response




 In the lbr+Ven arm, most patients with uMRD <10⁻⁴ had deep responses of uMRD <10⁻⁵

uMRD concordance in PB/BM, %	lbr + Ven	Clb + O
At <10-4	92.9	43.6
At <10 ⁻⁵	90.9	36.8

uMRD in patients with unmutated IGHV CLL

- With Ibr+Ven, depth of MRD response was similar in BM and PB for patients with unmutated IGHV CLL
- Among patients with mutated TP53, 5 of 7 achieved uMRD <10⁻⁵ in both BM and PB with Ibr+Ven

uMRD in PB from EOT+3 to EOT+12




Patients with sustained uMRD, %	Ibr+Ven	Clb+O
uMRD <10-4	84.5	29.3
uMRD <10 ⁻⁵	80.4	26.3

- uMRD <10⁻⁴ rate decreased 6% with lbr+Ven vs 27% with Clb+O
- Patients with detectable MRD ≥10⁻⁴ in the lbr+Ven arm were less likely to convert to PD vs those in the Clb+O arm or have worsening of detectable MRD levels

Phase 2 CAPTIVATE Study


 CAPTIVATE (PCYC-1142) is an international, multicenter phase 2 study evaluating first-line treatment with 3 cycles of ibrutinib followed by 12 cycles of combined ibrutinib + venetoclax with 2 cohorts: MRD and FD



- Primary analyses of both cohorts have been previously reported^{1,2}
- Presented are updated results from the MRD cohort, with median time on study: 38.2 months (range, 15.0–47.9)
 - Median postrandomization follow-up: 24.0 months (range, 5.8–33.1)

MRD, minimal residual disease; FD, fixed-duration. 1. Wierda WG et al. ASH 2020. Abstract #123. 2. Ghia P et al. ASCO 2021. Abstract #7501.

MRD Cohort: Patient Disposition and Randomization (cont.)




BM, bone marrow; PB, peripheral blood.

^aIncludes 1 patient who discontinued venetoclax but completed planned treatment with ibrutinib. ^bDid not meet criteria for uMRD because of detectable MRD in PB and/or BM *or* undetectable MRD in PB that was not confirmed at consecutive assessments.

ASH 2021, CAPTIVATE-MRD; Ghia et al.

3-Year PFS Rates Were ≥95% Across All Randomized Arms



Median follow-up = 38 months

- With an additional year of follow-up since the primary analysis, only 1 new PFS event occurred on study; a patient in the uMRD Not Confirmed ibrutinib arm who had PD after 42 months
- 36-month OS was 99% overall (97%–100% across randomized treatment arms)

PFS, progression-free survival; Plb, placebo. Tick marks indicate patients with censored data.

ASH 2021, CAPTIVATE-MRD; Ghia et al.

MODULE 2: Relapsed/Refractory (R/R) CLL: Novel Investigational Strategies – Dr Smith



A 71-year-old man with CLL who received pirtobrutinib in combination with venetoclax/rituximab on a clinical trial



Dr Shaachi Gupta (Lake Worth, Florida)



Use of monoclonal antibody therapy for COVID-19 prevention and treatment



Dr Vignesh Narayanan (Lone Tree, Colorado)



Relapsed/Refractory (R/R) CLL; Novel Investigational Strategies


RTP Symposium ASCO 2022

Mitchell R. Smith

NCCN CLL/SLL Guidelines: Relapsed/Refractory Regimens

		R/R without del(17p)/TP53 mutation			
	Preferred	Other recommended regimens			
Frail w/significant comorbidities OR ≥65 y and younger pts w/significant comorbidities	 Acalabrutinib (category 1) Ibrutinib (category 1) Venetoclax + rituximab (category 1) Duvelisib Idelalisib + rituximab 	 Alemtuzumab ± rituximab Chlorambucil + rituximab Reduced-dose FCR HDMP + rituximab Idelalisib Lenalidomide ± rituximab Obinutuzumab Ofatumumab Reduced-dose PCR Venetoclax Zanubrutinib (for patients with intolerance or contraindication to other BTKi) Dose-dense rituximab Bendamustine, rituximab ± ibrutinib, or idelalisib 			
< 65 y without significant comorbidities	 Acalabrutinib (category 1) Ibrutinib (category 1) Venetoclax + rituximab (category 1) Duvelisib Idelalisib + rituximab 	 Alemtuzumab ± rituximab Bendamustine + rituximab FC + ofatumumab FCR HDMP + rituximab Idelalisib Lenalidomide ± rituximab Obinutuzumab Ofatumumab PCR Venetoclax Zanubrutinib (for patients with intolerance or contraindication to other BTKi) Bendamustine, rituximab + ibrutinib 			
	R/R with del(17p)/TP53 mutation				
	Preferred	Other recommended regimens			
	 Acalabrutinib (category 1) Ibrutinib (category 1) Venetoclax + rituximab (category 1) Duvelisib Idelalisib + rituximab Venetoclax 	 Alemtuzumab ± rituximab HDMP + rituximab Idelalisib Lenalidomide ± rituximab Ofatumumab Zanubrutinib (for patients with intolerance or contraindication to other BTKi) 			


Kinomes of BTK Inhibitors



BID vs QD Dosing

Free Drug Concentration Time


Zanubrutinib



Efficacy depends on covalent, prolonged BTKi Toxicity may depend on peak vs AUC?

Kaptein, et al. Blood. 2018. 132 (Supplement 1): 1871. doi.org/10.1182/blood-2018-99-109973.


RESONATE Final Analysis, 6-year F/U of PFS: Ibrutinib vs Ofatumumab in Previously Treated CLL/SLL




RESONATE PCYC-1112; Munir T et al. Am J Hematol. 2019;94:1353-63

Months

Ibrutinib Outcome by Prior Lines of Therapy




- PFS rates at 5 years higher for ibrutinib treatment in earlier lines (first-line: 70%; 1-2 prior lines: 60%; ≥3 prior lines: 33%)
- Treatment in earlier lines resulted in better PFS for patients with high-risk prognostic features



OS rates at 5 years higher for ibrutinib treatment in earlier lines (first-line: 83%; 1-2 prior lines: 72%; ≥3 prior lines: 58%)
 Median OS for overall population not reached for first-line and 1-2 prior, and was 67 months for ≥3 prior lines

Barr PM et al. Blood. 2019;134(Suppl 1):Abstract 3054.

BR ± Ibrutinib for R/R CLL/SLL Phase III HELIOS




Chanan-Khan AAA, et al. Lancet Oncol. 2016;17:200-211.

Acalabrutinib Monotherapy in R/R CLL (ASCEND)



Crossover from IdR/BR allowed after confirmed PD

IRC-Assessed PFS Superior for Acalabrutinib vs IdR/BR Overall Survival (Median Follow-Up, 16.1 Months)




Ghia, P et al JCO 2020


ELEVATE-RR: PHASE III COMPARISON ACALABRUTINIB vs IBRUTINIB FOR RELAPSED/REFRACTORY CLL [with del(17p) or del(11q)]: NON-INFERIORITY DESIGN AND SAFETY ENDPOINTS: Median follow-up: 41 months

100

60

40





HR (95% CI): 0.34 (0.21 to 0.54)


Acalabrutinib: Ibrutinib HR (95% CI): 0.52 (0.32 to 0.86)

		BRUTINIB = 266	IBRUTINIB N = 263		
GRADE	All	≥ 3	All	≥ 3	
Afib	9%	5%	16%	4%	
НВР	9%	4%	23%	9%	
AE to DC	15%		21%		

ALPINE: Phase 3 Rel/Ref CLL Comparing Zanubrutinib and Ibrutinib


≥ 1 prior line; no prior BTKi
Median age 67 yrs
19% del17p and/or mutp53
Data cutoff 1 yr after 415th pt randomized


PFS by Investigator Assessment



DID PR-L COMPROMISE THIS RESULT? For del17p (N=50 total): ORR 83% vs 54%


TOXICITY





Hillman P et al EHA 2021


MURANO Study Design VR vs. BR



- · Primary endpoint: investigator-assessed PFS
- · Secondary endpoint: rates of clearance of MRD
- Clinical response and MRD* in PB during Ven monotherapy and follow-up visits were assessed every 3 months for 3 years, then every 6 months thereafter, or until PD


*Undetectable MRD defined as <1 CLL cell/10,000 leukocytes, determined by ASO-PCR or flow cytometry per iwCLL recommendations for reporting of MRD. BR, bendamustine–rituximab; D1C1, day 1, cycle 1; D1C2-6, day 1, cycles 2-6; EOCT, end of combination treatment; EOT, end of treatment; MRD, minimal residual disease; PB, peripheral blood; PD, progressive disease/disease progression; R, randomization; R/R, relapsed/refractory VenR, venetoclax–rituximab

MURANO 5-Year Follow-Up: Overall and Progression-Free Survival (All Patients)




Ma S et al. Blood 2021;138(10):836-46.

MURANO: PFS by Depth of Response (MRD) at End of Treatment



Seymour JF et al. *N Engl J Med.* 2018;378(12):1107-1120. Kater AP et al. *J Clin Oncol.* 2020;JCO2000948.

Venetoclax Responses Durable in Patients with CLL Relapsed/Refractory After Prior Ibrutinib and/or Idelalisib



- In patients with CLL R/R to ibrutinib and/or idelalisib treated with venetoclax monotherapy, median PFS was 24.7 months
- Median DoR and median OS were not reached after 24 months of follow-up

Median number of prior therapies in all patients: 4 (1-15)

Byrd JC et al. *J Clin Oncol.* 2018;36(Suppl 15):Abstract 7512; Jones JA et al. *Lancet Oncol.* 2018;19(1):65-75; Coutre S et al. *Blood.* 2018;131(15):1704-1711.

What About Treatment Post-Venetoclax?


MURANO: post-Ven-R treatment outcomes

	ALL	Novel Agents	BTKi	Ven-based
N =	99	52	18	32
ORR	71%	79%	100%	72%
Median duration (mos)	6	14	22	11

Harrup RA et al. ASH 2020 A3139.

A. Response to initial ven regimen (n=25)

B. Response to ven re-treatment regimen (n=18)



Abbreviations: CR: complete response, PR: partial response, SD: stable disease, PD: progression of disease

Therapy Post-Venetoclax Discontinuation in CLL:

Multicenter, retrospective cohort study (31 centers internationally, UK CLL Forum and Collaborative Study of Real World Evidence (CORE)

Post-Ven Therapy	BTKi	ВТКі	вткі	PI3Ki	CAR-T	Anti-CD20 abs
Agents	Ibrutinib Ibrutin Acalabrutinib Non-covale		Ibrutinib Acalabrutinib Non-covalent BTKi	Idelalisib Duvelisib	Anti-CD19	Rituximab Obinutuzumab Ofatumumab
Pre-Ven Exposure	BTKi-naïve	BTKi-exposed BTKi-resistant			BTKi- exposed	
Patient Number	44	20	10	17	18	19
ORR	83.9%	53%	70%	46.9%	66.6%	32%
CR	9%	6.6%	20%	5.9%	33.3%	16%
PR	56.8%	26.4%	30%	35.2%	33.3%	16%
PR-L	18.1%	20%	20%	5.8%	0%	0%
SD	11.6%	20%	-	23.7%	5.7%	32%
PD	4.5%	27%	30%	29.4%	27.7%	37%

Ven DC'c	for:
CLL PD	38%
AE	14%
Richter	14%
Pt pref	8%
alloSCT	6%


Mato AR et al. *Blood.* 2019;134(Suppl 1):Abstract 502.

What about Combining BTKi + BCL2i? Already in 1st Line Ibrutinib-Venetoclax in R/R CLL: BM MRD4 Responses

Treatment schema

	C1	C2	C3	C4>27		
Ibrutinib	420mg daily	420mg daily	420mg daily	420mg daily		
Venetoclax	-	-	-	20mg daily 1 week; 50mg daily 1 week; 100mg daily 1 week; 200mg daily 1 week; 400mg daily continuous		
				ombination treatment alone continues until PD		
 74 patients initiated combination 5 patients off-study during ibrutinib monotherapy 						
		_	_			

Median follow-up 27 months



Jain N et al. Blood. 2019;134(Suppl 1):Abstract 359.

Summary of Approved PI3K Inhibitors

	Idelalisib	Copanlisib	Duvelisib	Umbralisib
Isoform	δ	αδ	γδ	δ (and CK1-epsilon)
FDA-approved indications	 R CLL (w/rituximab) R SLL (≥2 prior systemic tx) R FL (≥2 prior systemic tx) 	 R FL (≥2 prior systemic tx) 	 R/R CLL (≥2 prior systemic tx) R/R SLL (≥2 prior systemic tx) R/R FL (≥2 prior systemic tx) 	 R/R MZL (≥1 prior anti- CD20 based tx) R/R FL (≥3 prior systemic tx)
Use w/o rituximab	No—CLL Yes—SLL FL	Yes	Yes	No
Method of administration	Oral	IV	Oral	Oral
Dosing	150 mg twice daily	60 mg as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle	25 mg twice daily	800 mg orally once daily with food
Black box Warnings	Hepatotoxicity, diarrhea or colitis, pneumonitis, infection, intestinal perforation	None	Infection, diarrhea or colitis, cutaneous reactions, pneumonitis	None

ZYDELIG® (idelalisib) tablets, for oral use [prescribing Information]. Foster City, CA: Gilead; Revised 10/2018. Aliqopa[™] (copanlisib) for injection [prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; Revised 2/2020 Copiktra® (duvelisib), capsules for oral use [prescribing information]. Needham, MA: Verastem; Revised 7/2019. UKONIQ[™] (umbralisib) tablets, for oral use [prescribing information]. Edison, NJ: TG Therapeutics, Inc; Revised 2/2021.


What's on the Horizon?

- New BTKi: non-covalent
- New BCL2i: which members of BCL2 family need to be affected
- New PI3Ki: dosing/scheduling being re-evaluated
- New antibody-based therapy: Targets (ROR1); ADC; Bispecifics
- Immune modulatory agents
- CART
- COMBINATIONS/SEQUENCES
- What do we do when everything has been used in initial therapy?
 - CLONAL DYNAMICS/Mechanisms of Resistance to personalize therapy

Non-Covalent BTK Inhibitors

- Resistance to covalent BTKi often due to mutation in binding site
- Non-covalent BTKi are not inhibited by such mutations
- Pirtobrutinib (LOXO-305) blocks the ATP binding site in BTK, with minimal offtarget inhibition
 - ARQ-531 hydrogen binds to amino acids 475&476, may block downstream of PLCgamma2 (another mechanism of BTKi resistance)
- In Phase 1/2 BRUIN trial no MTD was reached, RP2D is 200 mg/d >100 mg/d inhibited BTK at > IC90 throughout the dosing interval
- Most common Gr 3-4 AE neutropenia (10%); well tolerated
- In CLL/SLL (N=121) with prior BTKi, ORR = 62%
 - Prior BTKi resistance 67%
 - Prior BTKi intolerance 52%
 - C481 mutant 71%/BTK wt 66%

BRUIN: Updated Pirtobrutinib Efficacy Findings




Mato AR et al. ASH 2021;Abstract 391.

BRUIN: Updated Pirtobrutinib Safety Findings

		All doses a	and patients	(n=618)			
		Treatment-e	emergent AEs, (≥	15%), %		Treatment-re	elated AEs, %
Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Any Grade	Grades 3/4	Any Grade
Fatigue	13%	8%	1%	-	23%	1%	9%
Diarrhea	<mark>1</mark> 5%	4%	<1%	<1%	19%	<1%	8%
Neutropeniaª	1%	2%	8%	6%	18%	8%	10%
Contusion	15%	2%	4	-	17%	-	12%
AEs of special interest ^b							
Bruising	20%	2%	-	-	22%	-	15%
Rash⁴	9%	2%	<1%	-	11%	<1%	5%
Arthralgia	8%	3%	<1%	-	11%	-	3%
Hemorrhage ^e	5%	2%	1% ^g	-	8%	<1%	2%
Hypertension	1%	4%	2%	-	7%	<1%	2%
Atrial fibrillation/flutter ^f	-	1%	<1%	<1%	2% ^h	-	<1%


No DLTs reported and MTD not reached 96% of patients received ≥1 pirtobrutinib dose at or above RP2D of 200 mg daily 1% (n=6) of patients permanently discontinued due to treatment-related AEs

Will Other BH3 Mimetics Be Useful?



D'Aguanno Cells 2020 May; 9(5): 1287

Lisaftoclax (APG-2575), efficacy in patients with CLL/SLL (ORR = 80%) SLIDE COURTESY OF DR. ASHER CHANANKHAN




001-003: The nodal size reduction reached by 48% after 4 cycles of treatment at 100mg. The patient dose escalated to 200mg and achieved PR after 1 cycle of treatment at 200mg.

- Median (range) treatment of 9 cycles (Range 5-24 cycles)
- 12 of 15 evaluable R/R CLL/SLL patients achieved partial response (PR) by 2008 iwCLL definition, for an objective response rate of 80%
- Median time to response of 2 cycles (Range 2-8 cycles)



Anti-ROR1 Cirmtuzumab in CLL



Zilovertamab vedotin (ZV; previously VLS-101), ADC of cirmtuzumab, Phase I Wang M et al NEJM 2021

7/15 ORR MCL, not very active in CLL but N = 7

MODULE 3: Follicular Lymphoma (FL) – Dr Leonard



A 76-year-old woman with Stage III, Grade 1/2 FL now requiring treatment



Dr Shams Bufalino (Park Ridge, Illinois)



A 77-year-old man with newly diagnosed Grade I to II/III FL and a Ki-67 score of 80%



Dr Philip Brooks (Brewer, Maine)



A 77-year-old woman with EZH2 wild-type R/R FL who received tazemetostat



Dr Spencer Bachow (Boca Raton, Florida)



Updates in follicular lymphoma

John P Leonard, MD


Richard T Silver Distinguished Professor of Hematology and Medical Oncology Senior Associate Dean for Innovation and Initiatives Executive Vice Chair, Joan and Sanford I Weill Department of Medicine Weill Cornell Medicine New York, New York



How to treat advanced stage, high tumor burden FL? One approach: Bendamustine-Rituximab vs R-CHOP


PFS (StiL)

OS for FL patients




Weill Cornell Medicine

PRIMA: Maintenance R after R-CHOP/R-CVP improves PFS but not OS



Weill Cornell Medicine

GALLIUM: Obinutuzumab vs Rituximab with chemotherapy (and as maintenance)




and a second second

Marcus R, et al. N Engl J Med. 2017; 377:1331-44.



GALLIUM: Obinutuzumab vs Rituximab with chemotherapy (and as maintenance) improves PFS but not OS

PFS



Marcus R, et al. N Engl J Med. 2017; 377:1331-44.

Weill Cornell Medicine


Can we give Obinutuzumab short infusions? Gazelle study

- Phase IV study of Obinutuzumab administered in 90 min infusion in upfront FL patients from cycle 2 onwards
 - -Cycle 1 day 1, 8, 15 standard rate, if no G3 IRR, onward 90 min
- 113 patients, only one had grade 3 tox with subsequent 90 min infusion rate
- > 90% pts completed infusions in under 2 hours
- Now FDA approved regimen

Hubel et al, ICML 2021 Trask et al, ASH 2021




RELEVANCE: Lenalidomide-Rituximab (R2) vs Chemo-R




Morschhauser F, et al, NEJM 2018



RELEVANCE: Lenalidomide-Rituximab (R2) vs Chemo-R Similar ORR and CR as initial therapy for FL






Morschhauser F, et al, NEJM 2018

Weill Cornell Medicine

RELEVANCE: Lenalidomide-Rituximab (R2) vs Chemo-R Similar PFS and OS as initial therapy for FL



Morschhauser F, et al, NEJM 2018



Long term f/u of RELEVANCE study

- Median f/u 6 years
- 6 year PFS 60% R2 vs 59% R chemo
- Transformation rates similar (2% range)
- Similar ORR and OS with subsequent therapy in both groups
- Similar rates of second primary malignancies
- 6 year OS 89% in both groups

Morschhauser et al, ASH 2021




Key agents for recurrent FL

- Rituximab retreatment
- Obinutuzumab combination
- Radioimmunotherapy
- Lenalidomide + rituximab
- PI3K inhibitors
- EZH2 inhibitors
- Auto/Allo SCT
- CAR-T
- Novel agents



AUGMENT: R² vs rituximab monotherapy in R/R iNHL

≤ 12 cycles or until PD, relapse, or intolerability



- MZL or FL (grades 1-3a) in need of treatment
- ≥ 1 prior chemotherapy, immunotherapy
- or chemoimmunotherapy
- Not rituximab refractory


Primary endpoint: PFS by IRC (2007 IWG criteria w/o PET)

NCT01938001 1. Crawford et al. *Ann Oncol.* 2010;21 Suppl 5:248-251. 2. Smith et al. *J Clin Oncol.* 2015;33:3199-3212.

Leonard et al. JCO 2019



AUGMENT primary endpoint: Progression-free survival (ITT, IRC)



Median PFS	R² (n = 178)	R-placebo (n = 180)	HR (95% CI)	P Value
By IRC, mo (95% CI)	39.4 (22.9-NE)	14.1 (11.4-16.7)	0.46 (0.34-0.62)	< 0.0001
By investigator, mo (95% CI)	25.3 (21.2-NE)	14.3 (12.4-17.7)	0.51 (0.38-0.69)	< 0.0001


*Censoring rules based on FDA guidance.

Data cutoff June 22, 2018.

Leonard et al. JCO 2019



GADOLIN study: bendamustine vs bendamustine + obinutuzumab in rituximabrefractory iNHL




Sehn LH, et al. Lancet Oncol. 2016;17:1081-93.



GADOLIN study: obinutuzumab improves PFS and OS in recurrent iNHL when added to bendamustine

PFS



The addition of obinutuzumab also improved PFS in patients who were refractory to both alkylators and rituximab

- HR 0.56 (0.40-0.78)

Final analysis: Median OS was 88.3 months with the addition of obinutuzumab vs 65.6 months

- HR 0.77; p = 0.0810

Sehn LH, et al. Lancet Oncol. 2016;17:1081-93. Sehn LH et al. ASH 2019;Abstract 2822.




PI3K inhibitors with FL FDA indications withdrawn from market

- Idelalisib (Gopal NEJM 2014)
 - -ORR in iNHL 59%, median duration 11.2 mo
- Duvelisib (Zinzani ICML 2017)
 - -ORR iNHL 46%, median duration 9.9 mo
- Umbralisib (FDA 2021)
 - -ORR FL 43%, median duration 11.1 mo



PFS of Copanlisib in R/R Indolent Lymphoma



Median, mo	11.2	
Range	0.2-24.0	
95% CI	8.1-24.0	

ORR 59% (12% CR)

Dreyling M et al. J Clin Oncol. 2017;35:3898-3905.




Chronos-3 study (Copanlisib + Rituximab vs Placebo + Rituximab)

- Randomized trial of Copanlisib/R vs Placebo/R (Lancet Oncol 2021)
 - -307 pts, recurrent indolent lymphoma
 - -79% ORR/34% CR in C/R arm, 20.4 months DoR
 - -Favored C/R vs P/R by primary endpoint
 - Followup analysis (ASH 2021) longer response for those remaining on therapy vs d/c for toxicity but some durable responses after early discontinuation

Matasar et al, Lancet Oncol 2021

Follicular Lymphoma and EZH2

- EZH2 an epigenetic regulator of gene expression and cell fate decisions¹
- EZH2 is required for normal B-cell biology and germinal center formation²
 - Oncogenic mutations in *EZH2* suppress exit from germinal state and "lock" B cells in this state thereby transforming into a cancer²
- EZH2 biology relevant in both mutant (MT) and wild-type (WT) EZH2 FL
 - ~20% of patients with FL also have EZH2 gain of function mutations³



1. Gan L, et al. *Biomark Res.* 2018;6(1):10; 2. Béguelin W, et al. *Cancer Cell.* 2013;23(5)677-692. 3. Bödör C, et al. *Blood.* 2013;122:3165-3168. 4. Italiano A, et al. *Lancet Oncol.* 2018;19(5):649-59; 5. Morschhauser F, et al. *Hematol*

Tazemetostat, an investigational, selective, oral inhibitor of EZH2 has shown antitumor activity in non-Hodgkin's lymphoma patients with either MT or WT EZH2^{4,5}



Tazemetostat ORR in EZH2 mutant and wild type populations (recurrent FL)

	EZH2 Mutant Cohort (n=45)		EZH2 WT Cohort (n=54)	
Parameter	Investigator	IRC	Investigator	IRC
ORR, n (%)	35 (78)	31 (69)	18 (33)	19 (35)
CR, n (%)	4 (9)	6 (13)	3 (6)	2 (4)
PR, n (%)	31 (69)	25 (56)	15 (28)	17 (31)
SD, n (%)	10 (22)	13 (29)	16 (30)	18 (33)
PD, n (%)	0	1 (2) ^c	16 (30)	12 (22)
DOR, months, median (95% CI)	8.3 (5.5–13.8)	10.9 (7.2–NE)	14.7 (7.6–NE)	13.0 (5.6–NE)

Morschhauser, ICML 2019



Structure of selected BITE and bispecific antibodies

Bispecific Antibody	Targets	Design	Ig Fragment Formats	
blinatumomab	CD19 x CD3		 two murine scFv joined by a glycine-serine linker monovalent CD19 and monovalent CD3 binding cloned from anti-CD19 (clone HD37) and anti-CD3 (clone L2K-07) murine mAbs 	
mosunetuzumab	CD20 x CD3		 humanized mouse heterodimeric IgG1-based antibody monovalent CD20 and monovalent CD3€ binding modified Fc devoid of FcyR and complement binding 	4
glofitamab	 modified Fc devoid of FcyR and complement binding fully human IgG4-based heterodimeric antibody monovalent CD20 and monovalent CD3€ binding 		 bivalent CD20 and monovalent CD3€ binding 	
odronextamab			6	
epcoritamab	 humanized mouse IgG1-based heterodimeric antibody monovalent CD20 and monovalent CD3 binding IgG1 Fc modified to minimize Fc-dependent effector functions and to control Fab-arm exchange of mAb half-molecules, resulting in high bispecific product yield 		7	

Ig, immunoglobulin; scEv, single-chain variable fragment; mAb, monoclonal antibody; Ec, fragment crystallizable; EcyR, Ec gamma receptor

¹Dufner V, et al. Blood Adv (2019) 3:2491; ²Goebeler ME, et al. J Clin Oncol (2016) 34:1104; ³Viardot et al. Blood (2016) 127(11):1410; ⁴Schuster SJ, et al. ASH 2019, Plenary Abstract 6;

⁵Hutchings M, et al. ASH 2020, Abstract 403; ⁶Bannerji R, et al. ASH 2020, Abstract 400; ⁻²Hutchings M, et al. ASH 2020, Abstract 406

Schuster et al, ICML 2021



Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study


Lihua E. Budde, MD¹; Sarit Assouline, MD²; Laurie H. Sehn, MD³; Stephen J. Schuster, MD⁴; Sung-Soo Yoon, MD, PhD⁵;

orts

Dok Hyun Yoon, MD, PhD⁶; Matthew J. Matasar, MD⁷; Francesc Bosch, MD, PhD⁸; Won Seog Kim, MD, PhD⁹; Loretta J. Nastoupil, MD¹⁰; Ian W. Flinn, MD, PhD¹¹; Mazyar Shadman, MD, MPH¹²; Catherine Diefenbach, MD¹³; Carol O'Hear, MD, PhD¹⁴; Huang Huang, MSc¹⁵; Antonia Kwan, MBBS, PhD¹⁴; Chi-Chung Li, PhD¹⁴; Emily C. Piccione, PhD¹⁴; Michael C. Wei, MD, PhD¹⁴; Shen Yin, PhD¹⁴; and Nancy L. Bartlett, MD¹⁶


J Clin Oncol 2022; 40(5):481-91.

Best Percentage Change from Baseline in Indolent NHL, Including Grade 1-3a FL



Weill Cornell Medicine

Adverse Events with Incidence ≥ 10%



Weill Cornell Medicine

(B)

- NewYork-Presbyterian

Budde LE et al. J Clin Oncol 2022;40(5):481-91.


Glofitamab, a Novel, Bivalent CD2O-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, PhD¹; Franck Morschhauser, MD, PhD²; Gloria Iacoboni, MD^{3,4}; Carmelo Carlo-Stella, MD⁵; Fritz C. Offner, MD, PhD⁶; Anna Sureda, MD, PhD⁷; Gilles Salles, MD⁸; Joaquín Martínez-Lopez, MD, PhD, MBA⁹; Michael Crump, MD¹⁰; Denise N. Thomas, MSc¹¹; Peter N. Morcos, PharmD¹¹; Cristiano Ferlini, MD¹¹; Ann-Marie E. Bröske, PhD¹²; Anton Belousov, PhD¹³; Marina Bacac, PhD¹³; Natalie Dimier, PhD¹⁴; David J. Carlile, PhD¹⁴; Linda Lundberg, PhD¹⁵; David Perez-Callejo, MD, PhD¹⁵; Pablo Umaña, PhD¹³; Tom Moore, MD¹²; Martin Weisser, MD¹²; and Michael J. Dickinson, MBBS, DMedSci¹⁶

J Clin Oncol 2021;39:1959-70.

6 rapid communi ations

Response to Glofitamab in Patients with R/R B-Cell Lymphomas



Hutchings M et al. J Clin Oncol 2021;39:1959-70.

128



- NewYork-Presbyterian

Glofitamab as Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Franck Morschhauser,¹ Carmelo Carlo-Stella,² Michael Dickinson,³ Tycel Phillips,⁴ Roch Houot,⁵ Fritz Offner,⁶ Corinne Haioun,⁷ Paolo Corradini,⁸ Martin Hutchings,⁹ Anna Sureda,¹⁰ Joaquin Martinez-Lopez,¹¹ Tomasz Wróbel,¹² Shang-Ju Wu,¹³ Linda Lundberg,¹⁴ Estefania Mulvihill,¹⁴ David Perez-Callejo,¹⁴ James Relf,¹⁵ Anesh Panchal,¹⁵ Kathryn Humphrey,¹⁵ Emmanuel Bachy¹⁶

¹CHU Lille, Service des Maladies du Sang, F-59000 Lille, France; ³Humanitas University and Humanitas Research Hospital, Milan, Italy; ³Peter MacCallum Cancer Centre, Royal Mebiourne Hospital and The University of Meibourne, Meibourne, Austrais; ³University of Mebigan Medical School, Ann Arbor, Michigan, USA; ⁵CHU de Rennes, Università de Rennes, INSERM U1236, EFS, Rennes, France; ¹Università i Ziekenhuis Gent, Ghent, Belgium; ¹Hopital Henri Mondor, AP-HP, Criteil, France; ¹Università of Milan, Italy; ³Rigshospitalet, Copenhagen, Denmark; ¹⁰Institut Català d'Oncologie Hospitalet, UIBELL, Università de Barcelona, Barcetona, Spain; ¹¹Hospital Universitario 12 de Octubre (H12O), Centro Nacional de Investigaciones Oncologicas (CNIO)-H12O and Universided Complutense de Madrid, Madrid, Spain; ¹¹Wiroclaw Medical University, ¹⁰Hospicea Civils de Lyon and Université Hospital, Talpel, Talwan; ¹⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland; ¹¹Roche Products Ltd, Welwyn Garden City, United Kingdom; ¹¹Hospicea Civils de Lyon and Université Bernard, Pierre-Bénte, France.

Accepted as an Oral Presentation at the 63rd ASH Annual Meeting and Exposition


Weill Cornell

Medicine

63rd ASH' Annual Meeting and Exposition

ASH 2021; Abstract 128.

Phase I/II Study of Glofitamab as Monotherapy or in Combination with Obinutuzumab for R/R FL



- Myelosuppression was more common with the combination
- CRS rates were high and comparable, and cases were mainly low gradel Cornel

⊣ NewYork-Presbyterian

Morschhauser F et al. ASH 2021; Abstract 128.

Key challenges in management of follicular lymphoma

- What will it take to "dislodge" watch and wait as a standard option?
 - Randomized trial with OS benefit? Clear QOL benefit? Evidence of "cure"?
- How will we ever define a "cure"?
 - Potentially "cured" patients can relapse 15+ years later
 - Should "functional cure" be the goal and how is that defined?
- How can we better choose individualized "QOL targeted" rx?
 - For regimens with similar OS, value of PFS benefit vs QOL
- Can we move to risk-adapted rx (induction, consolidation, maintenance)?
 - Prognostic scores, tumor/patient profiling, PET, MRD, ctDNA

MODULE 4: Mantle Cell Lymphoma (MCL) – Dr Lunning





A 77-year-old woman with newly diagnosed asymptomatic MCL with extranodal involvement

Dr Vignesh Narayanan (Lone Tree, Colorado)

A 56-year-old man with blastoid variant MCL with a TP53 mutation



An 83-year-old man with MCL and disease progression on acalabrutinib



Dr Shams Bufalino (Park Ridge, Illinois)



Mantle Cell Lymphoma



Wrestle Mania

Matthew Lunning D.O. FACP Associate Professor

A National Cancer Institute Designated Cancer Center




FRED & PAMELA BUFFETT CANCER CENTER

Objectives

- Discuss current use of Bruton Tyrosine Kinase (BTK) inhibitors (i) in 1st line and relapsed/refractory (rel/ref) mantle cell lymphoma (MCL)
- Discuss results from studies presented at ASCO 2022 in MCL
- Discuss trial outcomes with BTK in combination with other systemic therapies for patients with MCL
- Discuss the outcomes of pirtobrutinib in patients with rel/ref MCL
- Discuss new agents and strategies in MCL




BTK Cage Match






BTK Cage Match



Dreyling M et al. Lancet 2016; Wang et al. Leukemia 2019; Tam et al. Blood Advances 2021


Entering the Cage Match





Rule et al. Haematologica 2019

Starting The Cage Match






Jain et al. JCO 2022

Elimination Chamber






Elimination Chamber





Elimination Chamber











		lbrutinib + BR (N = 261)	Placebo + BR (N = 262)
Median age (rang	ge), years	71 (65-86)	71 (65-87)
≥ 75 years, n (%)		74 (28.4)	82 (31.3)
Male, n (%)		178 (68.2)	186 (71.0)
ECOG PS 1, n (%)		127 (48.7)	118 (45.0)
	Low risk	44 (16.9)	46 (17.6)
Simplified MIPI, n (%)	Intermediate risk	124 (47.5)	129 (49.2)
11(70)	High risk	93 (35.6)	87 (33.2)
Bone marrow inv	volvement, n (%)	198 (75.9)	200 (76.3)
Blastoid/pleomo	rphic histology, n (%)	19 (7.3)	26 (9.9)
Extranodal, n (%)		234 (89.7)	226 (86.3)
Bulky (≥ 5 cm), n	(%)	95 (36.4)	98 (37.4)
TP53 mutated, n	TP53 mutated, n (%)		24 (9.2)
TP53 mutation st	atus unknown, n (%)	121 (46.4)	133 (50.8)







Patients at Risk

Ibrutinib + BR	261	239 221	208 197	187 171	163	158	152 145	138	128	118	70	25	0
Placebo + BR	262	244 223	212 203	197 188	177	171	165 159	154	147	137	90	31	2



Wang et al. ASCO 2022 LBA 7502

	Ibrutinib + BR (N = 259)Any GradeGrade 3 or 4		Placebo + BR (N = 260)		
			Any Grade	Grade 3 or 4	
Any bleeding*	42.9%	3.5%	21.5%	1.5%	
Major bleeding	5.8%	-	4.2%	-	
Atrial fibrillation*	13.9%	3.9%	6.5%	0.8%	
Hypertension	13.5%	8.5%	11.2%	5.8%	
Arthralgia	17.4%	1.2%	16.9%	0	



Tag Teaming MCL




Legion of Doom



Tag Teaming MCL: Ibrutinib + R²


	All patients (n=50)
Age (years)	69 (45-85)
Sex	
Female	14 (28%)
Male	36 (72%)
ECOG performance status score 0–1	45 (90%)
MIPI score	
Low risk (<5.7)	8 (16%)
Intermediate risk (5.7-6.1)	15 (30%)
High risk (>6-2)	23 (46%)
Missing	4 (8%)
Ann Arbor stage IV disease	42 (84%)
Bone marrow involvement	34 (68%)
Refractory disease	8 (16%)
Number of previous therapies	2 (1-7)
Previous therapy	
Autologous stem-cell transplantation	21 (42%)
Allogeneic stem-cell transplantation	3 (6%)
Ibrutinib	4 (8%)
Lenalidomide	1 (2%)





Jerkeman et al. Lancet Haematology 2018

Tag Teaming MCL: Venetoclax + Ibrutinib




Tam C et al. NEJM 2018


Tag Teaming MCL: 3-year Follow-up

Figure 1. Progression free survival (Dashed lines represent 95% confidence interval)

Figure 2. Overall survival (Dashed lines represent 95% confidence interval)



4 of 5 MRD neg at 18 months remains off txt






Handunnetti et al. ASH 2019

New Opponent: Pirtobrutinib


Characteristics	MCL (n=134)
Median age (range), years	70 (46, 88)
Female / Male, n (%)	30 (22) / 104 (78)
Histology Classic Pleomorphic/Blastoid	108 (81) 26 (19)
ECOG PS, n (%) 0 1 2	82 (61) 50 (37) 2 (2)
Median number prior lines of systemic therapy (range)	3 (1, 9)
Prior therapy, n (%) BTK inhibitor Anti-CD20 antibody Chemotherapy Stem cell transplant ^b IMiD BCL2 inhibitor Proteasome inhibitor CAR-T PI3K inhibitor	120 (90) 130 (97) 122 (91) 30 (22) 23 (17) 20 (15) 17 (13) 7 (5) 5 (4)
Reason discontinued prior BTKi ^a Progressive disease Toxicity/Other	100 (83) 20 (17)

BTK Pre-Treated MCL Patients ^a	n=100
Overall Response Rate ^b , % (95% CI)	51% (41-61)
Best Response	
CR, n (%)	25 (25)
PR, n (%)	26 (26)
SD, n (%)	16 (16)
BTK Naive MCL Patients ^a	n=11
Overall Response Rate ^b , % (95% CI)	82% (48-98)
Best Response	
CR, n (%)	2 (18)
PR, n (%)	7 (64)
SD, n (%)	1 (9)





New Opponent: Glofitamab




Patients



Hutchings et al JCO 2021

Put Into Retirement in MCL: Lenalidomide post BTK




	L (n = 13)	L + R (<i>n</i> = 11)	L + other ($n = 34$)	Overall $(N = 58)$		
Lenalidomid	e treatment dur	ation, weeks				
Median	8.4	14.0	7.0	8.4		
Range	0.4 to 30.0	0.9 to 37.9	1.1 to 77.9	0.4 to 77.9		
Number of le	enalidomide cyc	les				
Median	2.0	2.0	1.0	2.0		
Range	1.0 to 7.0	1.0 to 9.0	0.0 to 11.0	0.0 to 11.0		
Duration of a	Duration of other therapy combined with lenalidomide, weeks					
Median	NA	8.3	7.2	7.4		
Range	NA	0.1 to 35.9	0.7 to 77.7	0.1 to 77.7		



Wang M et al. J Hema & Onc 2017

Put Into Retirement in MCL: Venetoclax Post BTKi

All patients (N = 20)	n (%)
Gender	
Male	17 (85%)
Female	3 (15%)
First-line therapy	
CHOP \pm R or CHOP-like	6
Fludarabine-based $\pm R$	4 ^a
Maxi-CHOP/HDAC $\pm R$	8
Other	2 ^b
ASCT consolidation in first remission	
Yes	6 (30%)
No	14 (70%)
Rituximab maintenance in first remission	n
After immunochemotherapy	2 (10%)
After ASCT	0 (0%)
Neither	18 (90%)
Duration of exposure to BTK inhibitor	
Median	4.77 months
Range	0.66 - 34.85 months
Response to prior BTK inhibitor	
Overall response	11/20 (55%)
Complete response	3 (15%)
Partial response	8 (40%)
Stable disease	4 (20%)
Progressive disease	5 (25%)
Reason for BTK inhibitor discontinuation	(n = 20)
Progressive disease	17
Stable disease	1
Toxicity	2





Eyre et al. Haematologica 2019


Elephant in The Ring





TP53 Matters

N=183 from MCL2 & MCL3 trials





CIRLL Study

- Zilovertamab + Ibrutinib
- MCL or CLL
- ORR of 81%
 - Historic ORR of 66%, the addition of zilovertamab to ibrutinib was favorable.
- CR rate observed in the MCL cohort was 35% compared with the historic ibrutinib monotherapy CR rate of 20%.
- Zilo and ibrutinib median PFS of 35.9 months in patients with MCL who were followed for a median of 14.4 months
 - Compared with 12.8 months with ibrutinib alone.
- ZILO-301 (Ibrutinib +/- Zilo) in MCL
- ZILO-302 (ZILO + Ibrutinib) with POD to ibrutinib



MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL) – Dr Sehn





A 23-year-old man with limited-stage DLBCL, germinal center B-cell (GCB) subtype

Dr Zametta Lamar Naples, Florida



A 72-year-old man with pleural effusion and tamponade who is diagnosed with large B-cell lymphoma

Dr Shams Bufalino Park Ridge, Illinois



An 88-year-old woman with newly diagnosed DLBCL who developed pneumonia after the first dose of R-CHOP



Dr Erik Rupard (West Reading, Pennsylvania)



Diffuse Large B-Cell Lymphoma (DLBCL)

Laurie H. Sehn, MD, MPH Chair, Lymphoma Tumour Group BC Cancer Centre for Lymphoid Cancer Vancouver, Canada


Novel Agents Recently Approved in R/R DLBCL

	Pola-BR	Selinexor	Tafasitamab/ Lenalidomide	Loncastuximab Tesirine
MOA	Anti-CD79b ADC	XPO-1 inhibitor	Anti-CD19 MAb/Immunomodulat or	Anti-CD19 ADC
ORR	45%	28%	58%	48%
CR rate	40%	10%	40%	24%
PFS	9.2m	2.6m	11.6m	4.9m
DOR	12.6m	9.3m	43.9m	10.3m
OS	12.4m	NR	33.5m	9.9m

GO29365 Phase 1b/2 Study: Pola-BR in ASCT-Ineligible DLBCL


Inclusion: transplant-ineligible DLBCL, ≥1 line of therapy

Exclusion: prior allo-SCT; history of transformation; current grade >1 PN



*Pola 1.8 mg/kg on D1 of each cycle of BR; up to 6 cycles at 3-weekly interval

PFS and OS in Randomized and Extension Cohorts



Randomized cohort:


- Survival benefit persists with longer follow-up
- 2-y PFS: 28.4%, 2-y OS was 38.2%

Pooled cohort:

 Non-primary refractory patients: Median PFS: 13.4 m, median OS: 32 m

Sehn et al, Blood Advances 2022


Median PFS and OS in the Pooled Pola+BR cohort according to line of therapy and refractory status




Sehn et al, Blood Advances 2022

Tafasitamab and Lenalidomide: L-MIND Study

Phase 2, single-arm, open-label, multicenter study (NCT02399085)



- Sample size suitable to detect ≥15% absolute increase in ORR for Tafasitamab/LEN combination vs. LEN monotherapy at 85% power, 2-sided alpha of 5%
- Mature Data: Primary Endpoint Analysis with data cut-off 30 Nov 2018; minimum Follow-Up 12 months, median Follow-Up 17.3 months




Salles G et al, Lancet Oncology 2020

L-MIND: Efficacy (n=80)

ORR 60%, CR rate 43% by IRC


→ Median follow-up 33.9 months → Median PFS: 11.6 mos (95% CI: 6.3 - 45.7 mos)



Salles G et al, Lancet Oncology 2020, Duell J et al, Haematologica 2021


Loncastuximab Tesirine: Lotis-2 Trial Single Arm Open Label Phase 2 Study in DLBCL

Patient population: Patients with R/R DLBCL following ≥2 lines of prior systemic therapy Primary objective: Evaluate efficacy, using ORR (central review), and safety of the full Phase 2 study population



Caimi et al, Lancet Oncology 2021

Efficacy Results – OR



Caimi et al, Lancet Oncology 2021; Kahl et al, SOHO 2021

Glofitamab Pivotal Phase II Trial: Baseline characteristics

n (%)*		N=154 [†]	n (%)*	N=154
Median age, years (rar	nge)	66.0 (21–90)	Median no. of prior lines, n (range)	3 (2–7)
Male		100 (64.9)	2 prior lines	62 (40.3
ECOG PS [‡]	0	69 (44.8)	≥3 prior lines	92 (59.7
	1	84 (54.5)	Prior anti-CD20 Ab	154 (100.
Ann Arbor stage	I	10 (6.5)	Prior anthracycline	149 (96.
	II	25 (16.2)	-	· · · · · · · · · · · · · · · · · · ·
Ann Aibor Stage	III	31 (20.1)	Prior CAR-T	51 (33.1
	IV	85 (55.2)	Prior ASCT	28 (18.2
	DLBCL	110 (71.4)	Refractory to any prior therapy	139 (90.3
NHL subtype	trFL	27 (17.5)	Refractory to last prior therapy	132 (85.7
	HGBCL	11 (7.1)	Primary refractory	90 (58.4
	PMBCL	6 (3.9)		· · · · · · · · · · · · · · · · · · ·
.	>6cm	64 (41.6)	Refractory to prior CAR-T	46 (29.9
Bulky disease	>10cm	18 (11.7)	Refractory to any prior anti-CD20	128 (83. ⁻

Heavily pre-treated, highly refractory population

Clinical cut-off date: March 14, 2022; *unless otherwise specified; †safety-evaluable population (all treated patients); ‡ECOG PS 2, n=1 (0.6%); Ab, antibody; ASCT, autologous stem cell transplant; trFL, transformed follicular lymphoma.

Response rates – primary endpoint met

Efficacy endpoint ¹	Glofitamab 2.5/10/30mg (n=155)
CR rate*	61 (39.4%) [95% CI: 31.6%, 47.5%]
ORR*	80 (51.6%) [95% CI: 43.5%, 59.7%]


- Median duration of follow-up: 12.6 months (range: 0–22)
- Responses were achieved early: median time to first CR was 42 days (95% CI: 42, 44)
- At time of primary analysis, primary endpoint met in the primary efficacy population (n=108)[†]:
 35.2% CR rate by IRC significantly greater (p<0.0001) than 20% historical control CR rate[‡]

High CR/ORR rate at RP2D

*best response by intent-to-treat population; [†]the pivotal expansion cohort population; [‡]the historical control CR rate was pre-specified based on a meta-analysis in patients with R/R DLBCL (where most [\geq 50%] had received \geq 2 prior therapies) and compared with the CR rate in the primary efficacy-evaluable population using an exact binomial test (2-sided alpha level: 5%).

Dickinson et al, ASCO 2022

Time-to-event endpoints



Clinically significant freedom from progression at 12 months and long-term overall survival

*including five deaths due to COVID-19; †KM estimates

Dickinson et al, ASCO 2022

Glofitamab safety profile

n (%)*	N=154	AEs (≥15%) by grade and relationship with glofitamab				
Median no. of cycles received (range)	5 (1–13)					
Median relative dose intensity, % (range)	100 (94–100)	CRS	Any AE 63.0	Related AE 62.3		
AE Related AE	152 (98.7) 140 (90.9)	Neutropenia	37.7	31.2		
Grade 3–4 AE	87 (56.5)	Anemia	30.5	13.0 Grade		
Related AE	64 (41.6)	Thrombocytopenia	24.7	9.1 2		
Serious AE	73 (47.4)		21.7	9.1 3		
Related AE	46 (29.9)	Pyrexia	18.2	11.0		
Grade 5 (fatal AE)	8 (5.2)†	Hypophosphatemia	17.5	8.4		
Related AE	0	10		0 20 40 60 80 100		
AE leading to treatment discontinuation	14 (9.1)	100 80 60 40 20 0 20 40 60 80 Rate (%)				
Related AE	5 (3.2)			· · /		


Glofitamab was well tolerated, with a favorable safety profile

*unless otherwise specified; †COVID-19/COVID-19 pneumonia (n=5); sepsis (n=2); delirium (n=1); ‡includes neutrophil count decreased; §includes platelet count decreased; ¶pyrexia events separate from CRS

•

Dickinson et al, ASCO 2022

POLARIX: A randomized double-blinded study



*IV on Day 1; †R-CHOP: IV rituximab 375mg/m², cyclophosphamide 750mg/m², doxorubicin 50mg/m², and vincristine 1.4mg/m² (max. 2mg) on Day 1, plus oral prednisone 100mg once daily on Days 1–5. IPI, International prognostic index; ECOG PS, Eastern Cooperative Oncology Group performance status; R, randomized.


Tilly H et al, NEJM 2022

Baseline characteristics

ITT population		Pola-R-CHP (N=440)	R-CHOP (N=439)
Age	Median (range), years	65.0 (19–80)	66.0 (19–80)
Sex, n (%)	Male	239 (54)	234 (53)
ECOG PS, n (%)	0–1 2	374 (85) 66 (15)	363 (83) 75 (17)
Bulky disease (≥7.5cm), n (%)	Present	193 (44)	192 (44)
Elevated LDH, n (%)	Yes	291 (66)	284 (65)
Time from diagnosis to treatment initiation	Median, days	26	27
Ann Arbor Stage, n (%)	III–IV	393 (89)	387 (88)
Extranodal sites, n (%)	≥2	213 (48)	213 (49)
IPI score, n (%)	2 3–5	167 (38) 273 (62)	167 (38) 272 (62)
Cell-of-origin, (%)*	ABC GCB Unclassified	102 (31) 184 (56) 44 (13)	119 (35) 168 (50) 51 (15)
MYC/BCL2 expression, n (%)*	Double expression	139 (38)	151 (41)
MYC/BCL2/BCL6 rearrangement, n (%)*	Double-/triple-hit	26 (8)	19 (6)

Tilly H et al, NEJM 2022

Primary endpoint: Progression-free survival Pola-R-CHP significantly improved PFS versus R-CHOP



HR 0.73 (P<0.02) 95% CI: 0.57, 0.95

 Pola-R-CHP demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death versus R-CHOP

ITT population. Data cut-off: June 28, 2021; median 28.2 months' follow-up. NE, not evaluable.

 ²⁴⁻month PFS: 76.7% with Pola-R-CHP versus 70.2% with R-CHOP (Δ=6.5%)

		Pola-R-CHP (N=440)		R-CHOP (N=439)					
Baseline Risk Factors	Total N	n	2-year Rate	n	2-year Rate	Hazard Ratio	95% Wald Cl	Pola-R-CHP Better	R-CHOP Better
Age group ≤60 >60	271 608	140 300	74·1 77·9	131 308	71-9 69-5	0-9 0-7	(0·6 to 1·5) (0·5 to 0·9)		
Sex Male Female	473 406	239 201	75-9 77-7	234 205	65-9 75-2	0·7 0·9	(0·5 to 0·9) (0·6 to 1·4)		
ECOG PS 0–1 2	737 141	374 66	78·4 67·2	363 75	71·2 65·0	0-8 0-8	(0·6 to 1·0) (0·5 to 1·4)	, 	
IPI score IPI 2 IPI 3–5	334 545	167 273	79·3 75·2	167 272	78-5 65-1	1·0 0·7	(0·6 to 1·6) (0·5 to 0·9)		
Bulky disease Absent Present	494 385	247 193	82·7 69·0	247 192	70·7 69·7	0-6 1-0	(0-4 to 0-8) (0-7 to 1-5)	-	
Geographic region Western Europe, United States, Canada, and Australia Asia	603 160	302 81	78.6 74.3	301 79	72.0 65.6	0.8 0.6	(0.6 to 1.1) (0.4 to 1.5)		н н
Rest of world Ann Arbor stage I–II III IV	99 232 548	57 47 124 269	70.8 89·1 80·7 72·6	59 52 108 279	67.3 85·5 73·6 66·1	0.9 0·6 0·8 0·8	(0.6 to 1.5) (0.2 to 1.8) (0.5 to 1.3) (0.6 to 1.1)		
Baseline LDH ≤ULN >ULN	300 575	146 291	78·9 75·4	154 284	75-6 67-2	0.8	(0.5 to 1.3) (0.5 to 1.0)		-
No. of extranodal sites 0–1 ≥2	453 426	227 213	80·2 73·0	226 213	74-5 65-8	0·8 0·7	(0.5 to 1.1) (0.5 to 1.0)	-	4
Cell-of-origin GCB ABC Unclassified Unknown	352 221 95 211	184 102 44 110	75-1 83-9 73-0 73-8	168 119 51 101	76-9 58-8 86-2 64-3	1.0 0.4 1.9 0.7	(0.7 to 1.5) (0.2 to 0.6) (0.8 to 4.5) (0.4 to 1.2)		
Double expressor by IHC DEL Non DEL Unknown	290 438 151	139 223 78	75∙5 77∙7 76∙0	151 215 73	63 1 75 7 69 8	0·6 0·9 0·8	(0·4 to 1·0) (0·6 to 1·3) (0·4 to 1·5)		
Double- or triple-hit lymphoma Yes No Unknown	45 620 214	26 305 109	69·0 76·8 78·5	19 315 105	88-9 70-3 66-4	3·8 0·7 0·6	(0.8 to 17.6) (0.5 to 1.0) (0.4 to 1.1)		

? Benefit Younger ≤ 60y

Females

IPI = 2

Bulk \geq 7.5 cm


GCB Subtype

5

DH/TH lymphoma Tilly H et al, NEJM 2022

1


Overall survival



ITT population. Data cut-off: June 28, 2021; median 28.2 months' follow-up.

Tilly H et al, NEJM 2022


Patients receiving subsequent treatments



Data cut-off: June 28, 2021. *Subsequent lymphoma treatment was defined as non-protocol anti-lymphoma therapy; †Includes any monotherapy, multidrug, or cell-based regimen.

Tilly H et al, NEJM 2022

Common adverse events



Data cut-off: June 28, 2021. Adverse events are Medical Dictionary for Regulatory Activities version 24.0 preferred terms; shown are all-grade adverse events occurring in >12% of patients in any treatment arm. *Peripheral neuropathy is defined by standard organ class group of preferred terms.

Ongoing/Planned Trials in Upfront DLBCL

• BTK-inhibitor R-CHOP trials

– Escalade (acala); UK trial; zanubrutinib


• First-Mind Trial

- Tafasitamab/Lenalidomide + R-CHOP
- Bispecific antibodies + R-CHOP
- Biology-driven trials
- Response-adapted trials (ctDNA, quantitative PET/CT)

Glofit + R-CHOP shows encouraging clinical activity in R/R NHL

INV-assessed BOR rate (unconfirmed)	R/R NHL Dose-escalation phase (N=31)					
	Indolent NHL (FL + MZL) (n=24)	Aggressive NHL (trFL + MCL) (n=7)				
ORR*	22 (91.6)	6 (85.7)				
CMR	20 (83.3)	5 (71.4)				
PMR	2 (8.3)	1 (14.3)				
NMR	0	0				
PMD	1 (4.2)	1 (14.3)				
Missing/NE	1 (4.2)	0				

- In efficacy-evaluable patients (n=31), after a median 9.0 months' (range: 0–29) follow-up, the ORR was 90% (n=28); the CMR rate was 81% (n=25)
- Median duration of response was not reached in the R/R NHL cohort (range: 1–993 based on censored observation)



 Across all dose levels and histologies, Glofit + R-CHOP demonstrated encouraging anti-tumour activity in patients with R/R NHL

Ghosh et al, ASH 2021

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): phase 1/2 data update

Lorenzo Falchi, MD,^{1*} Fritz Offner, MD, PhD,² David Belada, MD, PhD,³ Joshua Brody, MD,⁴ Kim M. Linton, MBChB, PhD,⁵ Yasmin Karimi, MD,⁶ Raul Cordoba, MD, PhD,⁷ Sylvia Snauwaert, MD, PhD,⁸ Aqeel Abbas, MS,⁹ Liwei Wang, PhD,⁹ Jun Wu, MD, MS,¹⁰ Brian Elliott, MD,⁹ Michael Roost Clausen, MD, PhD¹¹

*Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, UBA, *Universitär Ziekenhund Gent, Gherd, Berglum, *ath Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Krälové, Cazeh Republic, *foath School of Medicine at Mount Sian, New York, NY, UBA, *The Christie NHS Foundation Trust and Manchester Cancer Research Center, Manchester, UK; *University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, UBA, *Fundacion Jimenez Diaz University dospital, Health Research Institute 118-FUD, Madrid, Spain, *Department of Hematology, A2 Sint-Jan Hospita, Bruges, Belgium; *Genmato Princeton, NJ, UBA, *Tabbite, North Chicago, IL, UBA, *Twele Hospital, Vele, Demmati, Vele, Cancer, AJ, UBA, *Topital, Vele, Demmati, Vele, Demmati, Vele, Demmati, Vele, Demmati, Vele, Pandacion, Vele, Vele, Nator, NJ, UBA, *Topital, Vele, Demmati, Vele, Vele

*Email address for questions: taichligmskcc.or

Objectives

- The EPCORE NHL-2 trial (phase 1/2; NCT04663347) is evaluating epcoritamab combined with different standard of care therapies in patients with B-cell NHL
- To present data from arm 1, which is investigating epcoritamab + R-CHOP in patients with previously untreated high-risk DLBCL

Conclusions


- Epcoritamab + R-CHOP showed encouraging responses:
 ORR 100%, CMR 77%
- Epcoritamab + R-CHOP has a manageable safety profile; no new safety signals were detected
 - CRS was predictable and generally low grade
- All CRS events resolved
- These updated data support further exploration of epcoritamab + R-CHOP in first-line DLBCL

Best Overall Responses

Response, n (%)ª	Total n=31
Overall response	31 (100)
CMR	24 (77)
PMR	7 (23)
Stable disease	0
Progressive disease	0

Data cutoff: March 25, 2022. ^aBased on modified response-evaluable population, defined as patients with ≥1 target lesion at baseline and ≥1 postbaseline response evaluation and patients who died within 60 d of first dose.

Response Profile



Falchi et al, ASCO 2022

MODULE 6: Chimeric Antigen Receptor (CAR) T-Cell Therapy – Dr Hill





A 75-year-old woman with recurrent DLBCL and significant cardiac comorbidity

Dr Vignesh Narayanan (Lone Tree, Colorado)

A 57-year-old man with double-hit DLBCL



An 84-year-old man with recurrent DLBCL



Dr Namrata Peswani (Richardson, Texas)



A 59-year-old man with R/R MCL and multiple comorbidities




Dr Spencer Bachow (Boca Raton, Florida)



Chimeric Antigen Receptor (CAR) T-Cell Therapy

Brian T. Hill, M.D., Ph.D. Director, Lymphoid Malignancies Program



Taussig Cancer Institute

Research To Practice*

AN INTEGRATED APPROACH TO ONCOLOGY EDUCATION

Research To Practice ASCO Update June 5, 2022






Long-Term Survival and Gradual Recovery of B Cells in Patients With Refractory Large B-Cell Lymphoma Treated With Axicabtagene Ciloleucel

Caron A. Jacobson, MD, MMSc¹; Fredrick L. Locke, MD²; Armin Ghobadi, MD³; David B. Miklos, MD, PhD⁴; Lazaros J. Lekakis, MD⁵; Olalekan O. Oluwole, MD, MPH, MBBS⁶; Yi Lin, MD, PhD⁷; Ira Braunschweig, MD⁸; Brian T. Hill, MD, PhD⁹; John M. Timmerman, MD¹⁰; Abhinav Deol, MD¹¹; Patrick M. Reagan, MD¹²; Patrick Stiff, MD¹³; Ian W. Flinn, MD, PhD¹⁴; Umar Farooq, MD¹⁵; Andre H. Goy, MD¹⁶; Peter A. McSweeney, MB, ChB¹⁷; Javier Muñoz, MD, MS, FACP¹⁸; Tanya Siddiqi, MD¹⁹; John M. Rossi, MS²⁰; Adrian A. Bot, MD, PhD²⁰; Lianqing Zheng, PhD²⁰; Remus Vezan, MD, PhD²⁰; Zahid Bashir, MBBS, MS²⁰; Jenny J. Kim, MD, MS²⁰; Rong Chu, PhD²⁰; and Sattva S. Neelapu, MD²¹

¹Dana-Farber Cancer Institute, Boston, MA, USA; ²Moffitt Cancer Center, Tampa, FL, USA; ³Washington University School of Medicine, St Louis, MO, USA; ⁴Stanford University School of Medicine, Stanford, CA, USA; ⁵Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA; ⁶Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; ⁷Mayo Clinic, Rochester, MN, USA; ⁸Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; ⁹Cleveland Clinic Foundation, Cleveland, OH, USA; ¹⁰UCLA David Geffen School of Medicine, Los Angeles, CA, USA; ¹¹Karmanos Cancer Center, Wayne State University, Detroit, MI, USA; ¹²University of Rochester School of Medicine, Rochester, NY, USA; ¹³Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; ¹⁴Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; ¹⁵University of Iowa, Iowa City, IA, USA; ¹⁶John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; ¹⁷Colorado Blood Cancer Institute, Denver, CO, USA; ¹⁸Banner MD Anderson Cancer Center, Gilbert, AZ, USA; ¹⁹City of Hope National Medical Center, Duarte, CA, USA; ²⁰Kite, a Gilead Company, Santa Monica, CA, USA; and ²¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Overall Survival At 4 Years (mITT, n=101)



- Among axi-cel-treated patients (mITT, n=101), with ≥4 years of follow-up (median, 51.1 months), median OS was 25.8 months, and the KM estimate of the 4-year OS rate was 44%
- Among the entire enrolled population (ITT, n=111), median OS was 17.4 months, and the KM estimate of the 4-year OS rate was 41%

Axi-cel, axicabtagene ciloleucel; KM, Kaplan-Meier; mITT, modified intent-to-treat; NE, not estimable; OS, overall survival.

CAR T-Cell and B-Cell Detection in Blood

- As previously reported, patients in ongoing response after 2 years had significantly greater peak CAR T-cell expansion in blood 7–14 days after axi-cel infusion than did patients with relapse (*P*=.014) or no response (*P*=.0003)¹
- Blood samples from 21 patients in ongoing response (per institutional standard of care) at ≥3 years were available for analysis of CAR T cells and evaluation of B-cell presence
 - All evaluable patients had detectable B cells in blood at 3 years after axi-cel treatment
 - 67% of patients (n=14/21) had detectable CAR gene-marked cells and polyclonal B cells in blood at 3 years

^{1.} Locke FL, et al. *Lancet Oncol.* 2019;20:31-42. Axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor.

Second Line CAR-T vs. Standard of Care


3 Randomized Phase III Trials*

- 1. ZUMA-7 Axi-cel
- 2. TRANSFORM Liso-cel
- 3. BELINDA Tisa-cel

*All required patients to have relapsed <12 months of completion of frontline treatment


ZUMA-7: Axi-cel vs. Standard of Care

94% of patients received axi-cel, whereas 36% of patients received HDT-ASCT




ZUMA-7: Axi-cel vs. Standard of Care

94% of patients received axi-cel, whereas 36% of patients received HDT-ASCT




ZUMA-7: Axi-cel vs. Standard of Care




Locke FL et al. NEJM 2022


TRANSFORM: Liso-cel vs. Standard of Care




TRANSFORM: Liso-cel vs. Standard of Care



TRANSFORM: Liso-cel vs. Standard of Care




	Liso-cel arm (n = 92)	SOC arm (n = 92)
Patients with events, n	35	63
Stratified HR (95% Cl)	0.349 (0.229–0.530) P < 0.0001	



Time from randomization, months

	Liso-cel arm (n = 92)	SOC arm (n = 92)	
Patients with events, n	13	24	
Stratified HR (95% CI)	0.509 (0.258–1.004) P = 0.0257		

BELINDA: Tisa-cel vs. Standard of Care




Bishop, et al. NEJM 2021

Confused?




Favorable Outcomes of ASCT in Complete Remission: Prognostic Value of Chemosensitivity



Sauter, et al Blood, 2015

Registry Comparison of patients in <u>PR</u> after ≤2 Lines of Prior Therapy




Proposed Approach

Refractory DLBCL

(Positive end-of-treatment PET scan after frontline treatment)

CAR-T cell

Proposed Approach



Frontline CAR-T for High Risk DLBCL



FOCUS ARTICLES


OPEN



Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Sattva S. Neelapu¹¹², Michael Dickinson², Javier Munoz³, Matthew L. Ulrickson³, Catherine Thieblemont^{4,5}, Olalekan O. Oluwole⁶, Alex F. Herrera⁷, Chaitra S. Ujjani⁸, Yi Lin⁹, Peter A. Riedell¹⁰, Natasha Kekre¹¹, Sven de Vos¹², Christine Lui¹³, Francesca Milletti¹³, Jinghui Dong¹³, Hairong Xu¹³ and Julio C. Chavez¹⁴

ZUMA-12 Study Design




* Administered after leukapheresis and completed prior to initiating conditioning chemotherapy; PET-CT was required after bridging.

1. Cheson BD, et al. J Clin Oncol. 2014;32:3059-3068.

Axi-cel, axicabtagene ciloleucel; BCL, B-cell lymphoma; CAR, chimeric antigen receptor; CR, complete response; CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; DOR, duration of response; DS, Deauville score; ECOG, Eastern Cooperative Oncology Group performance status; EFS, event-free survival; IPI, International Prognostic Index; IV, intravenous; LBCL, large B-cell lymphoma; mAb, monoclonal antibody; ORR, overall response rate; OS, overall survival; PET, positron-emission tomography; PFS, progression-free survival.

Frontline CAR-T for High Risk DLBCL



Caveat: Need prospective randomized control trial, as value of interim PET scan during R-CHOP has not been demonstrated. Continuation of R-CHOP may have resulted in favorable outcomes in a significant proportion of patients.


CAR-T for Mantle Cell Lymphoma: Brexu-Cel

Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).

Michael Wang, Javier Munoz, Andre Goy, Frederick Lundry Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Houston Holmes, Samantha Jaglowski, Ian Flinn, Peter A. McSweeney, David Bernard Miklos, Marie José Kersten, Krimo Bouabdallah, Max S. Topp, Rhine Shen, Ioana Kloos, Weimin Peng, Xiang Fang, Patrick M. Reagan

The University of Texas MD Anderson Cancer Center, Houston, TX; Banner MD Anderson Cancer Center, Gilbert, AZ; John Theurer Cancer Center, Hackensack, NJ; Moffitt Cancer Center, Tampa, FL; Dana-Farber Cancer Institute, Boston, MA; Cleveland Clinic Foundation, Cleveland, OH; UCLA David Geffen School of Medicine, Los Angeles, CA; Texas Oncology, Dallas, TX; The Ohio State University Comprehensive Cancer Center, Division of Hematology, Columbus, OH; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Colorado Blood Cancer Institute, Denver, CO; Stanford University School of Medicine, Stanford, CA; Amsterdam UMC, University of Amsterdam, and on behalf of HOVON/LLPC, Amsterdam, Netherlands; CHU Bordeaux, Service d'Hématologie et Thérapie Cellulaire, Bordeaux, France; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; Kite, A Gilead Company, Santa Monica, CA; University of Rochester Medical Center, Rochester, NY

CAR-T for Mantle Cell Lymphoma: Brexu-Cel




Assessed by an IRRC according to the Lugano Classification.7

*One patient was not evaluable.

CR, complete response; IRRC, Independent Radiology Review Committee; ORR, objective response rate; PD, progressive disease; with POD24, progression of disease <24 months after initial diagnosis; without POD24, progression of disease <24 months after initial diagnosis; PR, partial response; SD, stable disease.

• The ORR was similar among patients with and without POD24, with a slightly higher CR rate in patients without POD24 (Figure 2)

• Similar rates of MRD-negativity were also observed among patients with (82%; n=9/11) and without (79%; n=15/19) POD24



Wang, et al EHA 2021

CAR-T for Mantle Cell Lymphoma: Liso-Cel


Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001

M. Lia Palomba,¹ Leo I. Gordon,² Tanya Siddiqi,³ Jeremy Abramson,⁴ Manali Kamdar,⁵ Matthew Lunning,⁶ David G. Maloney,⁷ Charalambos Andreadis,⁸ Jon E. Arnason,⁹ Nilanjan Ghosh,¹⁰ Amitkumar Mehta,¹¹ Scott R. Solomon,¹² Thalia Farazi,¹³ Jacob Garcia,¹³ Christine Dehner,¹³ Ken Ogasawara,¹⁴ Jie Gao,¹³ Michael Wang¹⁵

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA; ³City of Hope National Medical Center, Duarte, CA, USA; ⁴Massachusetts General Hospital Cancer Center, Boston, MA, USA; ⁵University of Colorado Cancer Center, Aurora, CO, USA; ⁶University of Nebraska Medical Center, Omaha, NE, USA; ⁷Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁸Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; ⁹Beth Israel Deaconess Medical Center, Boston, MA, USA; ¹⁰Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; ¹¹University of Alabama at Birmingham, Birmingham, AL, USA; ¹²Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA, USA; ¹³Bristol Myers Squibb, Seattle, WA, USA; ¹⁴Bristol Myers Squibb, Princeton, NJ, USA; ¹⁵University of Texas MD Anderson Cancer Center, Houston, TX, USA

CAR-T for Mantle Cell Lymphoma: Liso-Cel


Best Overall Response by Investigator Assessment



- ORR and CR rate, respectively, for patients with high-risk features:
 - Ki67 ≥30% (n = 23): 83% and 65%
 - Blastoid morphology (n = 13): 77% and 54%
 - TP53 mutations (n = 7): 100% and 57%

CAR-T for Mantle Cell Lymphoma: Liso-Cel

Patient Responses over Time




CAR-T for Indolent Lymphoma: Axi-cel

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

THE LANCET

Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz, Gilles Salles, Pashna N Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A Leslie, Ibrahim Yakoub-Agha, Olalekan O Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P Avanzi, Sattva S Neelapu

CAR-T for Indolent Lymphoma: Axi-cel



Jacobson, et al. Lancet, 2022

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma Press Release: May 27, 2022

"On May 27, 2022, the Food and Drug Administration granted accelerated approval to tisagenlecleucel for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

The approval was based on the ELARA trial (NCT03568461), a multicenter, single-arm, open-label trial evaluating tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR) T cell therapy, in adult patients who were refractory or relapsed within 6 months after completion of two or more lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or relapsed after autologous hematopoietic stem cell transplant."




TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda,¹ Kathleen A. Dorritie,² Javier Munoz,³ Deborah M. Stephens,⁴ Scott Solomon,⁵ Heidi H. Gillenwater,⁶ Lucy Gong,⁶ Lin Yang,⁶ Ken Ogasawara,⁷ Jerill Thorpe,⁶ Tanya Siddiqi⁸


¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; ³Banner MD Anderson Cancer Center, Gilbert, AZ, USA; ⁴Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; ⁵Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA, USA; ⁶Bristol Myers Squibb, Seattle, WA, USA; ⁷Bristol Myers Squibb, Princeton, NJ, USA; ⁸City of Hope National Medical Center, Duarte, CA, USA

TRANSCEND CLL 004 Phase 1/2 Study Design¹ of liso-cel, a CD19-Directed, Defined Composition, CAR T Cell Product



^aNo patient in the combination phase 1 cohort received nonconforming product. ^bDefined as SD or PD as best response, or PD after previous response. ^cComplex cytogenetic abnormalities, del(17p), *TP53* mutated, or unmutated *IGHV*. ^d*BTK* or *PLC*₁/2 gene mutation, with or without progression on ibrutinib. ^eLower dose was used if prior dose reduction was necessary to manage toxicity. ^fMRD was assessed in blood by flow cytometry and/or in bone marrow by next-generation sequencing (both with a sensitivity of ≤10⁻⁴). CY, cyclophosphamide; DL, dose level; FLU, fludarabine; iwCLL, International Workshop on CLL; mTPI, modified toxicity probability interval; SD, stable disease. 1. ClinicalTrials.gov. NCT03331198; 2. Guo W, et al. *Contemp Clin Trials*. 2017;58:23-33; 3. Hallek M, et al. *Blood*. 2018;131:2745-2760. Wierda, *et al.* ASH 2020

Best Overall Response and uMRD ($\leq 10^{-4}$) at 10-Month Follow-Up



- No patients had PD during the first month after liso-cel
- One patient at DL1 had SD for 6 months but later progressed

^aEvaluated according to iwCLL 2018 criteria. ^bAssessed in blood by flow cytometry and/or in bone marrow by NGS. CRi, CR with incomplete blood count recovery; NGS, next-generation sequencing.

Cellular Kinetics-Expansion and Persistence

Median (Q1–Q3) p01 (Q1–Q3) 🔶 All - Subgroup ene (copies/µg), / 10³ Transger 01 100 22 29 11 15 Study Day Transgene (copies/µg), Median (Q1-Q3) 105 104 10³ 102 DL1 + ibrutinib DL2 + ibrutinib 10¹

11

8

15

Study Day

100

1 4

Parameter ^{a, b}	Monotherapy Cohort (N = 23)
C _{max}	67,300
(copies/µg)	(2510–139,000)
t _{max}	15
(day)	(14–21)
AUC _{0-28d}	470,000
(day × copies/µg)	(17,400–1,740,000)

*Median (interquartile range, Q1-Q3). ^bEvaluated using qPCR. ^cDefined as patients whose disease progressed on BTKi and failed venetoclax due to progression, intolerance, or failure to respond after at least 3 months of therapy.

Long-term persistence
50% of patients (n = 6/12) at 12 months
18% of patients (n = 2/11) at 18 months

Parameter ^{a,b}	Combination Cohort (N = 19)
C _{max}	128,000
(copies∕µg)	(47,100–344,000)
t _{max}	11
(day)	(10-15)
AUC _{0-28d} (day × copies/µg)	682,000 (390,000–2,720,000)

^aMedian (interquartile range, Q1-Q3). ^bEvaluated using qPCR.

- Long-term persistence
 - 38% of patients (n = 6/16) at 6 months
- -20% of patients (n = 1/5) at 12 months

Liso-cel + ibrutinib

Liso-cel

22

29

Cellular Kinetics-Expansion and Persistence


Median (Q1–Q3) p01 (Q1–Q3) 🔶 All - Subgroup ene (copies/µg), / 10³ at least 3 months of therapy. Transger 101 100 22 29 11 15 Study Day Transgene (copies/µg), Median (Q1-Q3) 105 104 10³ 102 DL1 + ibrutinib DL2 + ibrutinib 10¹ 100 29 15 22 11 1 4 8

Study Day

Parameter ^{a, b}	Monotherapy Cohort (N = 23)
C _{max}	67,300
(copies/µg)	(2510–139,000)
t _{max}	15
(day)	(14–21)
AUC _{0-28d}	470,000
(day × copies/µg)	(17,400–1,740,000)

*Modian (interquartile range, Q1-Q3). ^bEvaluated using qPCR. ^cDefined as patients whose disease progressed on BTKi and failed venetoclax due to progression, intolerance, or failure to respond after at least 3 months of therapy.


Long-term persistence
50% of patients (n = 6/12) at 12 months
18% of patients (n = 2/11) at 18 months



- Long-term persistence
- 38% of patients (n = 6/16) at 6 months
- -20% of patients (n = 1/5) at 12 months

Liso-cel + ibrutinib

Liso-cel



AUC_{0-28d}, area under the curve for transgene levels from 0 to 28 days postinfusion; C_{max}, maximum transgene levels; Q, quartile; t_{max}, time to C_{max}.

Breakfast with the Investigators: Urothelial Bladder Cancer

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting **Monday, June 6, 2022**

6:45 AM - 7:45 AM CT (7:45 AM - 8:45 AM ET)

Faculty

Yohann Loriot, MD, PhD Elizabeth R Plimack, MD, MS Jonathan E Rosenberg, MD

> Moderator Neil Love, MD



Thank you for joining us!

CME links will be posted in the chat (Zoom participants only) and emailed to all participants within 24 hours of the program.

